<DOC>
<DOCNO>EP-0659190</DOCNO> 
<TEXT>
<INVENTION-TITLE>
ANTINEOPLASTIC HETERONAPHTHOQUINONES.
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D31100	C07D31176	C07D31192	C07D33500	C07D33508	C07H1500	C07H15252	C07H1700	C07H1700	C07H1704	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	C07D	C07D	C07D	C07H	C07H	C07H	C07H	C07H	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D311	C07D311	C07D311	C07D335	C07D335	C07H15	C07H15	C07H17	C07H17	C07H17	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Tricyclic heteronaphthoquinone derivatives, that have antineoplastic activity, are disclosed, together with processes for their synthesis. Some of these anti-neoplastics compounds have a saccharide moiety. Some members of this structurally distinct group exhibit activity against multiple drug resistant cancer cells.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
IAF BIOCHEM INT
</APPLICANT-NAME>
<APPLICANT-NAME>
BIOCHEM PHARMA INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ATTARDO GIORGIO
</INVENTOR-NAME>
<INVENTOR-NAME>
BARBEAU FRANCE BOULEVARD DUDOM
</INVENTOR-NAME>
<INVENTOR-NAME>
BREINING TIBOR
</INVENTOR-NAME>
<INVENTOR-NAME>
COURCHESNE MARC
</INVENTOR-NAME>
<INVENTOR-NAME>
KRAUS JEAN-LOUIS
</INVENTOR-NAME>
<INVENTOR-NAME>
LAMOTHE SERGE
</INVENTOR-NAME>
<INVENTOR-NAME>
LAVALLEE JEAN-FRANCOIS
</INVENTOR-NAME>
<INVENTOR-NAME>
LEBEAU ELAINE
</INVENTOR-NAME>
<INVENTOR-NAME>
NGUYEN DIEU
</INVENTOR-NAME>
<INVENTOR-NAME>
REJ RABINDRA
</INVENTOR-NAME>
<INVENTOR-NAME>
ST-DENIS YVES
</INVENTOR-NAME>
<INVENTOR-NAME>
WANG WUYI
</INVENTOR-NAME>
<INVENTOR-NAME>
XU YAO-CHANG
</INVENTOR-NAME>
<INVENTOR-NAME>
ATTARDO, GIORGIO
</INVENTOR-NAME>
<INVENTOR-NAME>
BARBEAU, FRANCE 200 BOULEVARD DUDOMAINE
</INVENTOR-NAME>
<INVENTOR-NAME>
BREINING, TIBOR
</INVENTOR-NAME>
<INVENTOR-NAME>
COURCHESNE, MARC
</INVENTOR-NAME>
<INVENTOR-NAME>
KRAUS, JEAN-LOUIS
</INVENTOR-NAME>
<INVENTOR-NAME>
LAMOTHE, SERGE
</INVENTOR-NAME>
<INVENTOR-NAME>
LAVALLEE, JEAN-FRANCOIS
</INVENTOR-NAME>
<INVENTOR-NAME>
LEBEAU, ELAINE
</INVENTOR-NAME>
<INVENTOR-NAME>
NGUYEN, DIEU
</INVENTOR-NAME>
<INVENTOR-NAME>
REJ, RABINDRA
</INVENTOR-NAME>
<INVENTOR-NAME>
ST-DENIS, YVES
</INVENTOR-NAME>
<INVENTOR-NAME>
WANG, WUYI
</INVENTOR-NAME>
<INVENTOR-NAME>
XU, YAO-CHANG
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 ANT1 EOPLASΗC HETERONAPHTHOQUINONES This invention relates to heterocyclic naphthoquinone derivatives, to processes and to intermediates for preparing these derivatives, to pharmaceutical compositions containing them and to the use of these derivatives as antitumor agents in mammals.BACKGROUND OF THE INVENTIONAnthracycline antibiotics including doxombicin and daunorubicin are important chemotherapeutic agents in the treatment of a broad spectrum of neoplastic conditions. While daunorubicin (1) is clinically used mainly against acute childhood and adult leukemias, doxombicin (2), also known as adriamycin, has the widest spectrum of antitumor activity of all chemotherapeutic agents (Weiss, R.B., Saroβy, G., Clagett-Carr, K., Russo, M. and Leyland-Jones, B., Cancer Chemother. Pharmacol., 18, 185-197, 1986; Arcamone, F., Doxombicin, Academic Press, New York, 1980).(1) daunorubicin R = H(2) doxombicin R = OHThe usefulness of known anthracycline antibiotics is compromised by dose limiting toxicities such as myelosuppression (Crooke, S.K., Anthracychnes; Current Status and New Developments, Academic Press, N.Y. 1980) and cardiotoxicity (Olson, R.D. et al, Proc. Natl. Acad. Sci., USA 85 3585-3589, 1988 and references therein) as well as the resistance from treated tumors (Mimnaugh, E.G. et al, Cancer Research, 49, 8-15, 1989; McGiath, T. et al, Biochemical Pharmacology, 38 497-501, 1989). In view of the proven effectiveness of known anthncyclines in the treatment of cancer, efforts have been undertaken to develop anthracycline analogs with either an improved therapeutic index or with reduced cross-resistance. Several thousand anthracycline derivatives have been obtained either from streptomyces biosynthesis or via the semisynthetic modification of known natural anthracycline antibiotics (Arcamone, F., Doxombicin, Academic Press, N.Y. 1980; Thomson, R.H., Naturally Occurring Quinones m: Recent Advances, Chapman and Hall, New York 1987; Anthncyclines: Current Status and New Developments, Academic Press, New York, 1980; Brown, J.R. and Iman, S.H„ Recent Studies on Doxombicin and its Analogues, Prog. Med. Chem. 21 170-236, 1984; Brown, J.R. Adriamycin and Related Anthracycline Antibiotics, Prog. Med. Chem., .15, 125-164, 1978). The majority of known anthracychnes show two types of structural differences: (i) the substitution pattern of the aglycone tetracyclic ring system, and (ii) the structure and number of glycosides attached at C-7 or C-10 (doxombicin numbering). Some examples of the structural diversity of
</DESCRIPTION>
<CLAIMS>
 We claim:
A compound of he formula:

 or
12
wherein
X
]
 and X
2
 are independently selected from the groiφ consisting of O, S, and N(R), wherein R iβ selected from the group consisting of hydrogen, hydroxyl, C _ 
j
g alkyl, l-16 "*-*- *
*
"* ^1-16 ■lkylamine:
X3 is selected from the group consisting of O, S, SO, S ^, and NR, wherein R is selected from the group consisting of hydroxyl: 
c
l-16 * ■
>
 
c
l-16 "My-' 
c
l-16 "y
1
' 
c
l-16 
β
aloacyl, and hydrogen. X4 is selected from the group consisting of C-Q, nitrogen, and NO:
R
j
, R
2
, R3, and Q are independently selected from the groiφ consisting of hydrogen, hydroxyl, C
j
.
j
g alkyl, C
j
.
j
g alkoxyl, 0$.% cycloalkyl, tosyl, mesylate, acetate optionally substituted with a C
j
.g alkyl, triflate, trifluoroacotate, halogen, nitro, cyano, C
j
.
j
g acyl, C
j
. g aiylacyl, aminoalkylaminoalcohol of foπnula NH(CH )
n
NH(CH )
m
OH wherein n and m are independently 1 to 4, aminoalkylaminoalkylhalide of formula NH(CH )
n
NH(CH )
m
X wherein n and m are independently 1 to 4 and X is a halogen, amino, which may be unsubstituted or mono or di-substituted by C
j
.g alkyl, €3.3 cycloalkyl, C
j
.g acyl, trifluoroacyl, C .
j
g aralkyl and Cg_
j
g aryl; C2.8 alkenyl, and C2_
8
 alkynyl, haloalkylnitroβouieido of the foπnula NH(CO)N(NO) (CH^ CH
2
X, wherein n is 0 to 4 and X is a halogen, and
-NH(Cfl2)n N R* R** wherein n is 1 to 6, R* and R** are independently selected from hydrogen, C
j
.g alkyl, Cg_ g aryl, Cγ.
j
g aralkyl, C
j
.g acyl, and trifluoroacyl, a groiφ of the formula -0-C(R)=0 wherein R is selected from the groiφ consisting of hydrogen, C
j
.
j
g alkyl, C3_g cycloalkyl, C2.12 alkoxyalkyl, C .
j
g aralkyl, C . g araloxyalkyl, C7_ g aryloxyalkyl and C6.J8 aryl:
Z is one of C-Rg or C-R7.
R
<
j
 is selected from the group consisting of C
j
.
j
g hydroxime, Cg. g hydrazone, C
j
.jg hydroxyalkyl, hydrogen, C
6
.
j
g aryl, C7_ aryloxyalkyl, C
7
. g araloxyalkyl, phenyl, Cj.jg alkyl, acetoxy, C .
16
226
■
 m ^*
>
 ^ t ~
B
 ~ 1~~
>
.3 . I i m T 


dihydroxyalkyl, C^.g alkenyl, ^.g alkynyl, C
3
.g cycloalkyl, squaric acid, C
j
.
j
g alkyl squarate, amino, cyano, dimethylphoβphonato, phenyl sulfone, C .g aryl sulfone, and
C
j
.g acetyl, agroup of the formula -C(R) = X* wherein X is selected from the group consisting of two hydrogens, one hydrogen and R* is selected from a Cl-8 alkyl, C2-8 alkenyl, C7-18 aralkyl, and O, or its dioxolane or dioxane or dialkoxy Cl-8 ketal, and wherein R is selected from the group consisting of hydrogen, C
j
.
j
g alkyl, C
j
.g thioalkyl, C
3
.g cycloalkyl, Cg.
j
g aryl, C
7
.
j
g aralkyl, fluoromethyl, difluoromethyl, C
j
.g hydroxyalkyl, ^.
j
g alkene, squaric acid, ^.
j
g alkyne, C
j
.g ύiioalkyl, C
6
.
18
 thioaiyl, C
j
^ alkyl squarate, C^g alkoxyalkyl, Cg_ 8 araloxyalkyl, ^.
j
g acyloxyalkyl, Cj.g alkoxy, hydroxy, acetoxy methyl, bromomethyl, C
j
.g aceto, amino which may be unsubstituted or mono- or i- substituted by hydrogen, C
j
.g alkyl, C
3
.g cycloalkyl, C
j
.g acyl, trifluoroacyl, C7..18 aralkyl, Cg.
j
g aryl, a group of the formula -CHR* R**, wherein R* and R** are independently selected from the groiφ consisting of C
j
.g alkyl, hydrogen, PO (OR wherein R is selected firom the group consisting of hydrogen, C
j
.g alkyl, C
j
.g acyl, Cg. g aryl, ^
j
g aralkyl, and a group of the formula -(CH^Z* wherein n is O to 7 and Z* is from the group consisting of hydrogen, C
j
.g acyl, Cg_
j
g aryl, C .
j
g aralkyl, pyrolone, and a 5 or 6 membered aromatic or non-aromatic heterocycle containing one or more heteroatoms selected from de group consisting of O, S, N, SO, SO2, P, PO and NR wherein R is selected from the group consisting of hydrogen, hydroxyl, C
j
.g acyl, C
j
_4 alkyl and Cg. aryl; said heterocycle being optionally substituted with one or more halogens, hydroxy, Cg. g aryl sulfone, C
j
.
j
g alkoxy, C
j
.
j
g alkyl, nitro, C 
j
.
j
g hydroxyalkyl, amino, which may be unsubstituted or mono- or di-subβtituted by C
j
.g alkyl, C
3
.g cycloalkyl, C
j
_8 acyl, trifluoroacyl, C
7
.
j
g aralkyl, Cg_ 8 aryl, ^.g alkenyl, ^.g alkynyl and hydroxy, Z* can also be a group of the foπnula -NR* R** wherein R* and R** are independently selected from the group consisting of hydrogen, C .g alkyl, C
j
.g acyl, Cg.
j
g aryl, C7.J8 aralkyl, C .g haloal yl, C
j
.g hydroxyalkyl, C
j
.g alkoxyalkyl, C
j
.g acyloxyalkyl, Cg. 
2
 araloxyalkyl, and a group of formula 


 C(PO(OR)2)2 wherein n is 1 to 4 and R is hydrogen or C
j
.g alkyl; and a naturally occurring amino acid; a group of the formula -C(OR)*=0, where R is selected from the group consisting of hydrogen, C
j
.
j
g alkyl, C
3
_g cycloalkyl, C
j
.g hydroxyalkyl, C
j
.g alkoxyalkyl, Cη.m aryloxyalkyl, Cg.
j
g araloxyalkyl, C6.
18
 aiyl and C7.18 aralkyl; a group of the formula -{CH^ C(R)=0, wherein n is 1 to 6 and wherein R is selected from the group consisting of hydrogen, hydroxyl, C
j
.
j
g alkyl, C
3
.g cycloalkyl, C .g hydroxyalkyl, ^.g alkoxyalkyl,
Cj.8 alkoxy, C
7
.ι
8
 aiyloxyalkyl, C7.18 araloxyalkyl, C^jβ aiyl, C
7
.
18
 aralkyl, amino which may be unsubstituted, mono- or di-substituted by C
j
.g alkyl, C
3
.g cycloalkyl, acyl, trifluoroacyl, C . 
2
 aralkyl, Cg.
j
 aiyl, a 5 or 6 membered aromatic or non aromatic heterocycle containing one or more heteroatoms selected from the group consisting of O, S, N,
SO, SO2, P, PO, and NR wherein R is selected from the group consisting of hydrogen, oxygen, hydroxyl, acyl, C .4 alkyl and aryl,
227
SUBSTITUTE SHEET 


 said heterocycle being optionally substituted with one or more halogens, Cg. g arylsulfone, hydroxy, C
j
.
j
g alkoxy, nitro, C
j
.
j
g alkyl, Cj.jg hydroxyalkyl, amino which may be unsubstituted or mono- or disubstituted by C .g alkyl, C
3
.g cycloalkyl, acyl, trifluoroacyl, aralkyl or aryl; ^.g alkenyl, C^. alkynyl and hydroxy: R is selected from the group consisting of hydrogen, C
j
.
j
g alkyl, halogen, amino, hydroxy, C .
16
 alkoxy, thiol, cyano, sulfide, acyl of the formula -C(R)=0 wherein R is aelected from the group consisting of hydrogen, C
j
.
j
g alkyl, C
j
.
j
g alkoxy, C
3
.g cycloalkyl, C
j
.g hydroxyalkyl, Oy.
j
g araloxyalkyl, C2.g alkoxyalkyl, C2.8 acyloxyalkyl, C5.12 aryloxyalkyl, squaric acid or squarate, amino which may be unsubstituted or mono- or di-substituted by C
j
.g alkyl, C3_g cycloalkyl, C
j
_g acyl, cyano, trifluoroacyl, C7.18 aralkyl or Cg_i2 **yl. «-d - naturally occuring amino acid; a group of the formula -C(OR)«=0 wherein R is selected from the groiφ consisting of hydrogen, C
j
.
j
g alkyl, C3.8 cycloalkyl, C _8 hydroxyalkyl, C2-8 alkoxyalkyl, C .12 aryloxyalkyl, C7. 2 araloxyalkyl,
C5.J2 aryl, 
j
.
u
 aralkyl and C
j
.
j
g alkenyl: R5 and Rg are independently aelected from the groiφ consisting of hydrogen, halogen, hydroxyl, C
j
.
j
g alkoxyl, C
j
.
j
g alkyl, C2.I6 acetylenyl, a groiφ of the formula - CH
2
)
1J
-NR*R
, ,
 wherein n is 1 to 6, and R* and R** are independently selected from a group consisting of C
j
.g alkyl, C _4 acyl, C
3
.g cycloalkyl, hydrogen, C2.g caiboalkoxy, C^.g alkene, C2.8 alkyne, Cg.
j
 aryl, and 


 wherein R is a hydrogen or a C
j
.g alkyl and wherein n is 0 to 5;
C3-8 cycloalkyl, ^.
j
g alkenyl, C
j
.jg alkoxyalkylamino, cyano; a groiφ of the formula -O-C(R)=0, wherein R is selected from the groiφ consisting of hydrogen, C
j
.
j
g alkyl, C
3
.g cycloalkyl, C^.g alkoxyalkyl, and Cg. 
j
 aiyl; an acyl of the formula -C(R)=0, wherein R is selected from the groiφ consisting of hydrogen, thiol, C
j
. j
6
 thioalkyl, C .
j
g alkyl, C
3
.g cycloalkyl, C
j
.g hydroxyalkyl, C^.g alkoxyalkyl, C7.12 araloxyalkyl, C2.8 acyloxyalkyl, amino which may be unsubstituted or mono- or di-substituted, and a naturally occurring amino acid or a synthetic amino acid; a groiφ of the formula -C(OR)=0, wherein R is selected from the groiφ consisting of hydrogen, C
j
.
j
g alkyl and C
3
.g cycloalkyl, acoβamine, glucoβamine, N-cUoroethyl-nitroβoureidoglucosamine, 2,6- dideoxyifaamnose, thioglucoβe, thiodaunosamine, thiol, CJ.J thioalkyl, a naturally occuring amino acid or di- and tri-peptides thereof, a groiφ of the formula -Z*-CHRR* wherein Z* is selected from the group consisting of O, CH
2
, NR** wherein R** is from the group consisting of hydrogen, C
j
.g alkyl, C2.g acyl or Cg.^ aiyl,
R and R* are independently selected from the groiφ consisting of hydrogen, C . 
2
 alkyl, Cg. 
2
 aryl, C^.g dihydroxyalkyl, O
j
.g alkene, ^.g alkyne, C
j
.g alkoxy, C .g alkylamino, C
3
.g cycloalkyl, ^.g caiboalkoxy, a 5 or 6 membered aromatic or non-aromatic heterocycle containing one or more heteroatoms selected from the groiφ consisting of O, S, N, SO, SC^, P, PO, and NR wherein R is selected from the groiφ consisting of hydrogen, hydroxyl, C .g acyl, C .
228
SUBSTITUTE SHEET 


 4 alkyl and Cg. 
2
 a yl, said heterocycle being optionally substituted with one or more halogens, hydroxy, Cg_
j
g aryl sulfone, cyano C
j
.
j
g alkoxy, C
j
.
j
g alkyl, nitro, C
j
.
j
g hydroxyalkyl, amino, which may be unsubstituted or mono-or di-substituted by C .g alkyl, C
3
_g cycloalkyl, C
j
.
8
 acyl, trifluoroacyl, Cη.^ aralkyl, C _
j
8 aryl, C2_g alkenyl, C^. alkynyl and hydroxy; mono or oligoβaccharides of the formula:
wherein Y is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfone, CR*R**, wherein R* and R** are independently selected from the group consisting of hydrogen, C
j
.g alkyl, and NR wherein R is selected from the group consisting of hydrogen, C
j
.g alkyl, and C
j
.g acyl: R and RJQ are independently aelected from the group consisting of hydrogen, halogen, hydroxy, acetoxy, C
j
.
j
g alkoxy, C
j
.
j
g alkyl, C
3
.g cycloalkyl, tiiiol, amino, trifluoroacetamido, chloroethylnitroβoureido, and chloroethylureido:
Rll is selected from the groiφ consisting of hydrogen, amino which may be unsubstituted or mono or di-substituted by C .g alkyl, C
3
.g cycloalkyl, C2.g acyl, t-butylacyl, C
j
.g alkoxy, t- butyloxycarbonyl, trifluoroacyl, 7.J2 aralkyl, Cg. 
j2
 aryl, and a naturally occuring or synthetic amino acid; memo or dibenzylated amino, azido, acylated amino, trifluoroacylated amino, moipholino, cyano substituted morpholino, m mo-, di-, tri- or tetra-methoxy substituted morpholino, mono-, di-, tri- or tetra-acetoxy substituted morpholino, hydroxyl, hydrogen, halogen, acetoxy, C
j
.
j
g alkoxyl, C
3
.g cycloalkyl, diiol, βulfide; a groiφ of the formula NH(CH )„CH(OR)
2
 wherein R is selected from the groiφ consisting of C
j
.
j
g alkyl, C
j
.
j
g acyl and C .j aroyl and wherein n is 0 to 5. chloroalkylnitroβoureido of the formula NH(CO)N(NOXCH
2
)
n
CH
2
Cl wherein n is 0 to 4, and NH(CH2 2 OCH
2
CH(OA
c
)2:
R^ is selected from the group ccmsisting of hydrogen, hydroxyl or its tetrahydropropyl ether (-OTHP), mesylate, tosylate, halogen, mono or oligosaccharides, C
j
.g alkoxy, amino, mono or dialkylated amino in which each alkyl contains 1 to 16 caibon atoms, trifluoroacetamido, C
j
.
j
g alkoxy, C
3
.g cycloalkyl, C2.8 haloalkylacetate, benzoate which may be unsubstituted or substituted with nitro, one of the group ccmsisting of p-nitrobenzoate, acetoxy, trifluoroacetoxy, chloroalkylnitro-βoureido of he formula NH(CO)N(NOKCH2)nCH2Cl wherein n is 0 to 4, and NH(CH2)2 OCH
2
CH(OA
c
)2. R5 and R8 can also be independently selected from a 5 or 6 membered aromatic or non-aromatic heterocycle containing one or more heteroatoms, selected from the groiφ consisting of O, S, N, SO,
229
SUBSTITUTE SHEET 


Sθ2, P, PO and NR wherein R is selected from the group consisting of hydrogen, hydroxyl, C
j
.g acyl, C _4 alkyl and Cg.
j
 *ryl
»
 -*-- heterocycle being optionally substituted with one or more halogens, hydroxy, Cg„
j
g aryl sulfone, cyano, C
j
.
j
g alkoxy, C
j
.
j
g alkyl, nitro, C
j
.
j
g hydroxyalkyl, amino, which may be unsubstituted or mcmo-or di-substituted by C
j
.g alkyl, C
3
.g cycloalkyl, C
j
.g acyl, trifluoroacyl, C7.
j
g aralkyl, Cg_ g aryl, ^.g alkenyl, ^.g alkynyl and hydroxy.
2. A conφound according to claim 1 wherein
X 
j
 and X
2
 are independently selected from the groiφ ccmsisting of
O,
S, and
NH; X is selected from the groiφ consisting of
O,
S, c,
SO, SO2,
NH,
NO, and NOH
X4 is aelected from the groiφ consisting of
CQ, N, and
NO, Rj, R
2
, R3, and Q are independently selected from the groiφ consisting of hydrogen, hydroxyl, C
j
.4 alkoxyl, toβyl, triflate, fluorine, chlorine, amino, ami∞alkylaminoalcohol of formula NH(CH
2
)
n
NH(CH
2
)
m
OH wherein n and m are indqiendeatly 1 to 3, aminoalkylaminoalkylchloride of foπnula NH(CH )
n
NH(CH2)ι
n
Cl wherein n and m are independently 1 to 3,
230
SUBSTITUTE SHEET 


 cUoroalkylnitroβoureido of the foπnula NH(CO)N(NθχCH
2
)
n
 CH
2
 Cl, a group of the formula -O-C(R)=0, wherein n is 0 to 4, and wherein and wherein R is selected from ti e group consisting of hydrogen, C
j
.g alkyl,
■nd Cg_i2 aryl; Z is one of C-Rg, 01C-R7; R_g is selected from the group consisting of hydrogen, C
j
.g hydroxyalkyl,
C
j
.g dihydroxyalkyl, squaric acid, C
j
.
j
g alkyl squarate, C alkyl, acyl of the formula -C(R)=0, wherein R is selected from the groiφ ccmsisting of hyd ogen, C dkyl. C
j
.8 hydroxyalkyl, squaric acid C
j
_4 alkyl squarate,
C2.8 alkoxyalkyl, C . 
2
 acyloxyalkyl and amino which may be unsubstituted or mono- or di-substituted with C
j
.g alkyl, C
3
_8 cycloalkyl, C
j
.g acyl,
C
j
_8 trifluroacyl, C7.12 aralkyl or Cg.
j2
 aiyl; a group of die formula -C(OR)=0, wherein R is selected from the groiφ consisting of hydrogen, .8 «i yl, Cg-12 ^1.
C7.J2 aralkyl; and a group of die formula -CH
2
C(OR)=0, wherein R is selected from the group consisting of hydrogen, straight or branched C .g alkyl, and amino which may be unsubstituted or mono- or di-substituted with
C _
8
 alkyl, C3. cycloalkyl, C
j
_
8
 acyl, trifluoroacyl, C
7
.
j2
 aralkyl or Cg. 
2
 aryl;
231
SUBSTITUTE SHEET 


A 5 or 6 membered aromatic or non aromatic heterocycle containing one or more heteroatoms aelected from the groiφ consisting of O, S, N, NO, and NH; said heterocycle being optionally substituted witi one or more halogens, hydroxy, C
j
.g alkoxy, C .g alkyl, Cj.g hydroxyalkyl, amino, which may be unsubstituted or mono- or disubstituted by C
j
.4 alkyl, C3.5 cycloalkyl,
C
j
.g acyl, trifluoroacyl, Cg.
j2
 aryl, and hydroxy;
R7 is selected from the groiφ consisting of hydrogen, fluorine,
C
j
^ alkyl
C _4 alkoxy, cyano, acyl of the formula -C(R)=0, wherein R is selected from the groiφ consisting of hydrogen,
Cj.g alkyl,
C
j
.g hydroxyalkyl,
C2-8 acyloxyalkyl, amino, cyano, a groiφ of die formula -C(OR)=0, wherein R is selected from die groiφ ccmsisting of hydrogen,
C
j
_
8
 alkyl,
C .12 
β
rylt C
j
.g alkenyl;
R5 and Rg are independently aelected firom the group consisting of hydrogen, halogen, hydroxyl, C
j
.g alkoxy,
C2.8 acetylenyl, C2.8 alkenyl, cyano, a groiφ of the formula -O-C(R)=0, wherein R is selected from the group consisting of hydrogen, and
C
M
 alkyl; acyl of die formula -C(R)=0, wherein R is selected from the groiφ consisting of hydrogen, tiiiol,
232
SUBSTITUTE SHEET 


 C
j
_
8
 alkyl, C
j
.g hydroxyalkyl, amino; a group of the formula -C(OR)= O, wherein R is selected from the groiφ consisting of hydrogen, glucosamine,and
C
j
.galkyl, and a saccharide of formula
wherein
R9 and RJO are independently selected from the group consisting of hydrogen, fluorine, chlorine, hydroxyl, amino, and trifluoroacetamido;
R
j j
 is selected from die groiφ consisting of amino which may be unsubstituted or mono-or di-substituted with C
j
.g
■cetoxy. Cj_8 alkyl, C3.8 cycloalkyl, C2.8 acyl, trifluoroacyl, Cη.γ andkyl or Cg_ 2 aiyl; morpholino, cyano substituted morpholino, mono-, di-, tri-, or tetra-methoxy substituted morpholino, hydroxyl, mono or dialkylated amino with 1 to 16 caibons, C _
8
 alkoxyl, a group of die formula NH(CH
2
)
n
CH(OR)
2
 wherein R is independently selected from the group consisting of C
j
.g alkyl, C
j
.g acyl or C7.J2 aroyl and wherein n is 1 to 5; chloroalkylnitrosoureido of die formula
NH(CO)N(Nθ CH2 nCH2Cl wherein n is 0 to 4, NH(CH2)2 OCH
2
(OA
c
)2, fluorine; and
233
mJ mJ Ii t t - Lm +-*
>
 . Λ tm ώm I 


 Rj2 is selected firom the group consisting of hydroxyl or its tet ahydropyranyl ether, halogen, mono or oligosaccharide selected firom the groiφ consisting of from rhodosamine, cinerulose-B, L-cineruloβe, D-cineiυloβe, cinerulose A, amicetoβe, aculose, rednose, ifaodinose, 2-deoxyfucoβe, daunosamine; and trifluoroacetyldaunoβamine, amino, trifluoroacetamido, mono or dimethylated amino,
C .g alkoxy, benzoate, p-nitrobenzoate, chloroalkylnitrosσurea, acetoxy and trifluo oacetoxy.
3. A compound of die foπnula
12
Xj and X
2
 are independently selected from the groiφ consisting of
0, and
NH; X3 is selected from the groiφ consisting of
0, s,
SO, and NO; X iβ selected from the group ccmsisting of CQ, N, and NO,
234
SUBSTITUTE SHEET 


R
j
, R
2
, R3, and Q are independently selected firom the group consisting of hydrogen, hydroxy, methoxy, aπunoethylaminoethanol aminoethylaminoethylchloride chloroalkylnitrosoureido of die foπnula NH(CO)N(NO)(CH
2
)
I1
CH2Cl, wherein n is 0 to 2, amino, and fluorine;
Z is one of C-Rg or C-R7; Rg is selected from the group consisting of C alkyl, C _4 hydroxyalkyl, C
j
_4 dihydroxyalkyl, acyl of the formula -C(R)=0, wherein R is selected from the group ccmsisting of methyl, hydroxymethyl, acyloxymethyl and amino; a groiφ of the foπnula -C(OR)=0, wherein R is selected firom the groiφ consisting of hydrogen, methyl and ethyl; a groiφ of the foπnula -CH
2
C(OR)=0, wherein R is selected from the group consisting of hydrogen, methyl and ethyl;
A 5 or 6 membered aromatic or non aromatic heterocycle containing one or more heteroatoms selected from the group consisting of O.S, N, NO, and NH said heterocycle being optionally substituted with one or more halogens, hydroxy, C
j
.4 alkoxy, C
j
.4 alkyl, C
j
.4 hydroxyalkyl, amino which may be unsubstituted or mono- or disubstituted by methyl, cyclopropyl, C^. acyl, and hydroxy;
R7 is selected from the groiφ consisting of hydrogen, fluorine,
235
SUB^ i i i ϋ i E ncc l 


 mediyl, methoxy, cyano, acyl of the foπnula -C(R)=0, wherein R is selected from the group consisting of hydrogen,
C
j
_5 alkyl, C
j
.g hydroxyalkyl, amino, cyano, a group of the formula -C(OR)=0, wherein R is selected firom the groiφ ccmsisting of hydrogen, C
j
.5 alkyl,
C -i2 «yi.
C
j
.4 alkenyl;
R5 and Rg are independently selected from the groiφ consisting of hydrogen, halogen, hydroxy, methoxy, cyano,
acetyl and a saccharide of formula
wherein
R9 and RJO are independently selected from the group consisting of hydrogen, fluorine, and iodine R
j j
 is selected from the groiφ consisting of hydroxyl, acetoxy, amino,
236
SUBS i . a _____ cju. im___. ____. I 


 dimethylamino, trifluoroacetamido, morpholino, cyano substituted moipholino, mono-, di-, tri-, or tetra-methoxy substituted morpholino, a group of the foπnula NH(CH2)øCH(OR)2 wherein R is selected from the group consisting of C 
j
_4 alkyl C 
j
_4 acyl or C-j.ξ aroyl and wherein n is 2 to 5, chloroalkylnitroβoureido of die formula NH(CO)N(NOXCH2)
Q
CH2C1, wherein n is 0 to 4,
NH(C0
2
)OCH
2
)CH2CH(OA
c
)2; and
R 12 is selected from the group consisting of hydroxyl or its tetiahydropyranyl ether, benzoate, acetoxy, p-nitrobenzoβte,
trifluoroacetamido, chloroethylnitroβoureido, fluorine, and iodine.
4. A compound according to claim 1, wherein
X j and X2 are both oxygen;
X
3
 is
0, or S;
X4 is selected firom the group consisting of N, NO, or CQ;
Rj, R2, R3 and Q are each independently selected from the group consisting of hydrogen, fluorine, and hydroxyl; Z is one of C-R$ or C-R7; g is selected from the groiφ consisting of methyl, ethyl, hydroxymethyl,
1,2 dihydroxyeύiyl,
237
Jϋ j S U ϋ i ε Zr.t-Z i 


 acyl of the formula -C(R)=0, wherein R is selected from the groiφ consisting of methyl, fluoromethyl, difluoromethyl, hydroxymethyl, acetoxymethyl, and bromomethyl;
A 5 or 6 membered aromatic or non aromatic heterocycle containing one or more heteroatoms selected firom the group ccmsisting of O, S, N, NH, said heterocycle being optionally substituted with one or more fluorine, hydroxy, methoxy, methyl, hydroxymethyl, amino and acylamino groiφs.
R
7
 is selected from the group consisting of hydrogen, fluorine, methyl, and cyano, R5 and Rg are independently selected from the group consisting of hydrogen, hydroxyl, bromine, chlorine, cyano, acetate, acetyl, and a saccharide of die formula
wherein 9 and RJQ are independently selected from the groiφ consisting of hydrogen, fluorine, and iodine
R j is selected from the group consisting of amino,
238
SUBSTiTϋTΞ SHEET 


 hydroxy, dimethylamino, acetoxy, trifluoroacetamido, morpholino, cyano substituted morpholino, methoxymoipholino and a groiφ of the foπnula NH(CH
2
)
n
CH(OR)
2
 wherein R is selected from a group consisting of methyl, C
j
.g acyl or benzoyl and wherein n is 3 to 5, chloroalkylmtrosoureido of the formula NH(CO)N(NθχCH
2
)
11
CH2Cl, wherein n is 0 to 4, and NH(CH
2
)OCH2CH(OA
c
)2
R 12 is hydroxyl or iodine.
5. A compound according to claim 1 wherein :
X j and X
2
 are both oxygen;
X
3
 is O, or S;
X4 is CQ;
R
2
 and R
3
 are both hydrogen; R
j
 and Q are independently selected from the group consisting of hydrogen, fluorine, and hydroxyl;
Z is one of C-Rg or C-R
7
;
Rg is selected firom the groiφ ccmsisting of ethyl, hydroxymethyl,
1 ,2-dihydroxyedιyl, acyl of the foπnula -C(R)=0, wherein R is selected from the group ccmsisting of methyl, fluoromethyl, difluoromethyl, hydroxymediyl; R7 is hydrogen;
R5 and Rg are independently aelected from the group consisting of hydrogen, hydroxyl and acetyl.
6. A compound according to claim 1 wherein : X 
j
 and X
2
 are both oxygen; X3 is O, or S;
239
^ 1 I ft '*
>
 "-** * ~ ~" ~ • 
«
^" ir» ** t m —_•____. hUύ3 . . ι υ S.HfcET 


 X is CQ,
R
2
 and R3 are both hydrogen;
R
j
 and Q are independently selected from the groiφ consisting of hydrogen, fluorine, and hydroxyl; Z is one of C-Rg or C-R7;
Rg is selected from the group consisting of ethyl, hydroxymethyl,
1 ,2-dihydroxyethyl, carbonyl squarate, and acyl of the formula -C(R)=0, wherein R is aelected from the group consisting of mediyl, fluoromethyl, difluoromethyl, and hydroxymethyl;
R7 is aelected from the groiφ consisting of hydrogen, methyl, or fluorine, R5 and Rg are independently selected firom the groiφ consisting of hydrogen, hydroxyl, bromine, chlorine, cyano, acetate, acetyl and a saccharide of die formula

 wherein
R9 and Rio are independently selected from the groiφ consisting of hydrogen, fluorine, and iodine Rn is selected from the groiφ consisting of hydroxyl,
240 bu ^ s k t i iz ^razz 


 acetoxy, amino, dimethylamino, trifluoroacetamido, morpholino, cyano substituted morpholino, methoxymorpholino,
R]2 is selected from the groiφ consisting of acetoxy, hydroxyl, hydrogen, and iodine, with the proviso that at least one of R5 and Rg is saccharide;
7. A compound according to Claim 5 wherein R5 is hydrogen;
8. A compound according to Claim 5 wherein R5 is hydroxyl;
9. A compound according to Claim 4 wherein both R5 and Rg are independenϋy a saccharide of die formula:
wherein R9 and RIQ are independendy selected from hydrogen,
241
SUBSTITUTE SHEET 


 fluorine, and iodine;
Rll is selected from amino, dimethylamino ammonium chloride, trifluoroacetamido, morpholino, cyano substituted morpholino, methoxy møipbolino, and
R 12 is selected from the group consisting of hydrogen, hydroxyl, iodine, and acetoxy;
10. A compound according to claim 6 wherein cme of R5 and Rg is saccharide.
11. A compound according to claim 9 wherein R
j j
 is selected from the group consisting of hydroxyl, amino, and trifluoroacetamido;
12. A compound according to claim 10 wherein RJJ is selected from the groiφ consisting of hydroxyl, amino, and trifluoroacetamido;
13. A compound according to claim 3 wherein X3 is oxygen;
14. A compound according to claim 3 wherein X3 is sulfur;
242
SUBSTITUTE SHEET 


 15. A compound according to Claim 13 wherein both R5 and Rg are independently saccharide;
16. A compound according to claim 13 wherein one of R^and Rg is saccharide.
17. A compound according to Claim 14 wherein both R5 and Rg are independently saccharide;
18. A compound according to claim 10 wherein one of R5 and Rg is saccharide.
19. A compound according to claim 12 wherein Rg is hydrogen.
20. A compound according to claim 13 wherein Rg is hydrogen.
21. A compound according to claim 14wherein Rg is hydrogen.
22. A compound according to claim 15 wherein Rg is hydrogen.
23. A compound according to claim 16 wherein Rg is hydrogen.
24. A compound according to claim 17 wherein Rg is hydrogen.
25. A compound according to claim 18 wherein Rg is hydrogen.
26. A compound according to claim 1, wherein X3 is 0 or 5; and
Z is one of C-Rg or C-R7.
27. A conφound according to claim 26, wherein X3 is O; and R5 is methoxy or 3- (tetraethyl-3,3-bis phosphoric ester) propriamido- 2-yl ethoxy.
28. A compound according to claim 3 wherein X3 is O or S; and Z is one of C-Rg or C-R7.
29. A compound according to claim 28 wherein X3 is O; and R5 is methoxy or 3-
243
SUBSTITUTE SHEET 


 (tetraethyl-3,3-bis phosphoric eater) propriamido-2-yl ethoxy.
30. A compound according to claim 1 selected from the group consisting of
Methyl (5,10-dioxo-3,4,5,10-tetrahydronaphdιo [2,3-C] pyιan-3-yl) ketone (BCH-
1125);
Mediyl (7-hydroxy-5,10-dioxo-3,4^,10-tetrahydroo_φhtho [2,3-C] pyran-3-yl) ketone
(BCH-1129);
Mediyl (6-hydroxy-5,10-dioxo-3,4,5,10-tetrahydrooaρhdιo [2,3-C] pyran-3-yl) ketone; Monofiuoromediyl (5, 10-dioxo-3,4,5, 10-tetnhydronaphtiιo [2,3-C]
 pyπn-3-yl) ketone;
Bromomediyl (5, 10-dioxo-5, 10-dihydronaphtho [2,3-C] pyran-3-yl) ketone;
Σ-^.-Hydroxy-l'.Σ'.-dioxo-S'- cyclobutenoxy]
 mediyl (5,10- dioxo-3,4,5,10- tetnhydronaphύio [2,3-C] pyran-3-yl) ketone;
Trans-3-aceto-l-methoxy-l ,2,3 ,4-tetrahydro-(2-thia)anthracene-5, 10-dione and cis-3- aceto-l-medιoxy-l,2,3,4-tetCThydro-(2-thia)anthιacfne-5, 10-dione; cis-3-aceto-l-medκ
>
xy-l,2,3,4-tetnhydro-(2-thia) anthracene-5, 10-dione and t_nans-3-e_»to-l-methoxy-l,2,3,4-tetn_hydro-(2-thia) anthracene-5, 10-dione;
(l'S, lS,3R)-l-(2' ,3 * ,6'-trideoxy-3 '-βmino-L-lyxobexopyranoβe)-3-(2-aza-3- aminothiazolyl)-5,10-dioxo-3,4,5,10-tetιahydro-lH-naphdιo [2,3-C] pyran; (rS,lR,3S)-l-
<
2\3\6'-triQ^xy-3'-«niικ
>
-L-lyxohexopyτanoθe)-3-(2-aza-3- aminothiaw
>
lyl)-S, lO-dioxo-3,4,5, 10-totrahydro-lH-naphdιo [2,3-C] pyran
Methyl (l-hydroxy-5,10-dioxo-3,4,5,10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone
(BCH-1148); trans-3-aceto-l-hydroxy-l,2,3,4-tetrahydro-(2-thia) anthracene-5, 10-dione and cis-3- aceto-l-hydroxy-l,2,3,4-tetπhydro-(2-dιia) andιracene-5, 10-dione;
1'S,1S,3R mediyl (5,8-dioxo-l-(2',3',6'-trideoxy-3
,
-trifluoroa_xtaιmdo-L-4'-0-p- nitrobenzoyl-L-lyxohexopyianoee)-3,4,5,10- .tetrahydrobenzo [2,3-C] pyran-3-yI) ketone;
1'S,1R,3S mediyl (5,8-dioxo-l-(2\3 6'-tridTOxy-3
,
-trifluoroace mido-L-4
,
-0-p- nitroben2oyl-L-lyxohex(φyranose)-3,4,5,10-tetrahydrobenzo [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) mediyl (5,8-dimethoxy-l-(2\3',4 6
,
-tetnd___oxy-3'4
,
-diacetoxy-L-
Lyxohexo-pyτanoβe)-3,4,-dihydrobe_nzo [2,3-C] thiopyιan-3-yl);
(1'S,1R,3S) methyl (S.g-dimethox -H '^'^'.o'-tetradeoxy-S'^'-di ceto -L- Lyxohexopyranose)-3,4,-dihydrobenzo [2,3-C] thiopyπn-3-yl);
(l
f
S,lS,3R) methyl (5,8-dimethoxy-l-(2\3',4 6
,
-tetπ«ieoxy-3 4
,
-diacetoxy-
L-lyxohexopynιιose)-3,4,-dihydrobenzo [2,3-C] thiopyran-3-yl) ketone;
(1'S,1R,3S) methyl (S.β-dimethoxy-l- '.S'^'.β'-tetradeoxy-S'^'-diacetoxy-
L-lyxohexopyranose)-3,4,5,8, tetrahydrobenzo [2,3-C] thiopyran-3-yl) ketone;
244
SUBSTITUTE SHEET 


 l'S, IS, 3R- Meuiyl (5,10-dioxo-l-(2\3
,
,6
,
-trideoxy-3
,
-trifluoroacetamido-4*O-p- ritrobenzoyl-L-lyxohexopyranoβe)-3,4,5,10-tetrahydronaphdιo [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S- Methyl (5,10^oxc H2 3\6
,
-trid_»xy-3'-trinιwroa∞tamido-4'O-p- ritrobenzoyl-L-lyxohexopyτanose)-3,4,5,10-tetrahydronaphdιo [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S Mediyl (5,10-dioxo-l-(2\3 6
,
-trideoxy-3
,
-trifluoroacetamido^'-0-p- rit_robenzoyl-L-lyxohexopyrano_»)-7-hydroxy-3,4,5,10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; l'S, IS, 3R Mediyl (5,10-rioxo-l-(2\3 6
,
-trideoxy-3
,
-trifluoroa_»tamido-4
,
-O-
P
- ritrobenzoyl-L-lyxohexopyranoβe)-7-hydroxy - 3,4,5,10-tetrahydronaphtiιo [2,3-C] pyran-3-yl) ketone;
(1 'S, lS,3R)-Bromomethyl (5, 10-dιoxo-l-(2' ,3 ' ,6'-trideoxy-4'-0-P-nitrobenzoyl-3 '- trifluoroacetamiά^L-lyxohexopyranoβeH3,4,5,10-tetrahydronaphtho [2,3-C] pyran-3- yl) ketone;
(l'S,lR,3S)-Bromomethyl (S.lCl-dioxo-l^'.S'^'-trideoxy^'-O-P-ritrobenzoyl-S'- trifluoroacetamido-L-lyxohexopyranoβeH3,4,5,10-tetπ_hydronaphtho [2,3-C] pyran-3- yl) ketone;
(1'S,1S,3R) -2-{4
,
-hydroxy-l
,
,2
,
-dioxo-3'-cyclobutaioxy] methyl (5,10-dioxo-l- [2 3\6"-trideoxy-4"-0-p-ritroben_α)yl-3'-trifluoroa-_»t^
3,4,5,10-tetrahydronaphUιo [2,3,C] pyran-3-yl) ketone;
(1'S,1R,3S) ^^'-hydroxy-r^'-dioxo-S'-cyclobutenoxy] methyl (5,10-dioxo-l-
[2" ,3 " ,6"-trideoxy-4"-0-p-ritrobeι__zoyl-3 '-triflwmwcetamido-L-lyxohexopyranose]-
3,4,5,10-tetrahydronaphdio [2,3,C] pyran-3-yl) ketone; (l'S
t
lR,3S)-l-(2\3 6'-4rideoxy-4
,
-Oφ^trobenzoyl-3
,
-trifiuoιoacetamidc^L- lyxαhexopyraιιoβe)-3-(2-bronιoacetyl)-5,10-dioxo-3,4,5,l
&
[2,3-C]-pyran;
(l'S, IR, 3S)-l-(2\3\6
,
-trideoxy-4'-0-pH_itrobenzoyl-3
,
-triflι_oroacetaιrido-L- lyxohexopyπmoβe)-3-(2-aza-3-aminothiazolyl)-5, 10-dioxo-3,4,5, 10-tetrahydro-lH- naphdιo-(2,3-C)-pyιan;
(l'S,lR,3S)-l-(2\3\6'-trideoxy-3
,
-triflιιoroacetamid -4
,
-p-ritrobenzoyl-L- lyxohexopyranoβe)-3-(2-aza-3-«cetanudothiazolyl)-5,10-dioxo-3,4,5,10-tetπ_hydro-lH- naphdκ
>
-[2,3-C]-pyran;
(l'S,lS,3R)-H2\3'-6
,
-trideoxy-4'-p^t_robenzoyl-3
<
-trifluoro-acetamido-L- lyxc_hexcφyranoβe)-3-(2-bromoa^l)-5,10-dioxo-3,4,5,l
&
 [2,3-
C] pyran;
(l*S,lS,3R)-l-(2 3
,
-6'-trideoxy^'-0-p-ritrobenzoyl-3'-trifluoroacetairic_o-L- lyxohexopyranose)-3-{2-aza-3-acetamido)-5, 10-dioxo-3,4,5, 10-tetrahydro-lH-naphtho-
[2,3-C]-pyran;
245
SUBSTITUTE SHEET 


 (1'S,1R,3S) mediyl (H2',3\6
,
-trideoxy-3'-trifluorw_-_.eia__rido-4'-0-p-^^ lyxohexo^yranose]-5,10-dioxo-3,4,5,10-tetrahydro-7-methyl-9-a2a naphtho [2,3-C]
 pyran-3-yl ketone;
(1'S,1S,3R) methyl (H2\3\6'-trideoxy-3'-trifluoroacetamido-4'-O Miitrobenzoyl-L- lyxohexo-pyranoβe]-5,10-dioxo-3,4,5,10-tetrahydro-7-ιnethyl-9-a2a naphtho [2,3-C]
 pyran-3-yl ketone;
(l
,
S,lR,3S mediyl-l-
<
2 6
,
-dideoxy-3\4
,
-di-0-p-nitrobenzoyl-L- lyxohexopyraιrøβe)-5,10-dioxo-3,4,5,10-tet_rahydronaphtiιo [2,3-C] pyran-3-yl) ketone; (l'S,lS,3RVm_Λyl-l-(2',6'-dideoxy-3*,4'-di-Cτ
>
-ritrt*^^
5, lO-dioxo-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone;
(l'S, IR, 3R)-5,l()-rioxc
>
-3-eωyl-l-(2',3\4 6
,
-t_ radeoxy-3
,
,4
,
-diacetoxy-L- lyxohexopyranose)-3,4,5,10-tetrahydπ
>
-lH-naphtho [2,3-C] pyran;
(l'S, IS, 3S 5,10^oxo-3-ethyl-l-(2\3\4\6
,
-tetradeoxy-3
,
,4
,
-diacetoxy- - lyxcΛexopyranoβe)-3,4,5,10-tetrahydro-lH-naphtho [2,3-C] pyran;
(1'S,1S,3R) methyl (5,8-dioxo-H2
,
,3
,
I
 4',6'-tet__adeoxy-3',4'-diacetoxy-L- lyxobexopyranc∞)-3,4,5, 10-tetrahydronaphtho [2,3-C] thiopyran-3-yl) ketone; (1'S,1R,3S) mediyl (5,8-dioxo-l-(2
,
,3', 4',6'-tetndeoxy-3',4'-diacetoxy-L- lyxohexopyranose)-3 ,4,5, 10-tetrahydronaphtho [2,3-C] thiopyran-3-yl) ketone; l'S, IR, 3S Methyl (5,10-dioxo-l-(2 3\6'-trideoxy-3
,
-trifluoroacetaιrido-4
,
-hydroxy-
L-lyxohexopyranose)-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S Methyl (5,l()^oxc
>
-l-(2',3\6'-trideoxy-3
,
^
_unincH 
,
-hydroxy-L- lyxohexopyranose)-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; l'S, IS, 3R Mediyl (5,10-dioxo-l- 2 3 6'-trideoxy-3'-TrifllloroacetaIrido-4
,
- hydroxy-L-lyxohexoρyranoβe)- 3,4,5, 10-tetrahydronaphthό [2,3-C] pyran-3-yl) ketone; l'S, IS, 3R Methyl (5, 10-dιoxo-l-
<
2', 3', 6' -trideoxy-3 '-amino-4' -hydroxy-L- lyxohexopyrano__e)-3,4,5,10-tet_rahydronaphύιo [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S Mediyl (5,10^ox- l-(2\3\6
,
-trid_oxy-3'-trifluoroa_ t*mido-L- lyxohexopyιanoβe)-7-hydroxy - 3,4,5, 10-tetrahydro [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S Methyl (S.lO-dioxo-l-P'.S'.
β
'-trideoxy-S'- amino-L-lyxohexopynnose)-7- hydroxy-3,4,5, 10-tetrahydro [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) mediyl (5,10
<
Uoxo-l-(2',3',6
,
-trideoxy-3'-trifluoroacet_urido-_L- lyxohexopyιanose)-7-hydroxy - 3,4,5,10-tetrahydro [2,3-C] pyran-3-yl) ketone; (1'S,1S,3R) mediyl (
5,10-dioxo-l-(2
"
,3
'
,6
'
-trideoxy-3'- amino-L-lyxohexopyranose)-7- hydroxy- 3,4,5, 10- tetrahydro [2,3-C] pyran-3-yl) ketone;
(l'S,lR,3S)-l-(2\3
,
,6
,
-trideoxy-3'-trifluoroacetaιrido- -lyxohexopyιanoβe)-3-(2-aza- 3-acetamidodιiazolyl 5,10-rioxo-3,4,5,10-tetιahydro-lH4uφhtho [2,3-C] pyran; (1 'S, lR,3S)-l-(2' ,3 ' ,6 '-trideoxy-3 '-trifluoroacetamido-L-lyxohexopyranose)-3-(2-aza- 3-acetaιmdoUιiazol)-5,10-dioxo-3,4,5,10-tetrahydro-lH-ιιaphtho [2,3-C]
 pyran;
246
SUBSTITUTE SHEET 


 (l'S, lS^RH-φ' 
»
3 ' ,6'-trideoxy-3 '-trifluoroa∞taιrido-L-lyxohexopyranose)-3-(2-aza- 3-acetamido- thiazolyl)-5,10-dioxo-3,4,5,10-tetrahydτo-lH-naphdιo-[2,3-C]-pyran; (l'S,lS,3R l-(2',3',6'-trideoxy-3
,
-triflucm_acetamido-L-lyxohexopyr_mose)-3-(2-aza-
3-aminodιiazolyl)-5, lO-dioxo-3,4,5, 10-tetrahydro-lH-n___phdκ
>
-[2,3-C]-pyran; (1'S,1R,3S) MeΛyl(l-(2\3 6'-trid^xy-3
,
-βιnino-L-lyxohexopyranose)-5,10-dioxc
>
-
3,4,5, 10-tetr_dιydro-7-medιyl-9-azana{jhtho-[2,3-C]-pynn-3-yl) ketone;
(1'S,1S,3R) Medιyl(l-(2',3',6'-trideoxy-3'-amino-__^lyxohexopynnoβe)-5,10-dioxo-
3,4,5, 10-tetrahydro-7-methyl-9-azanaphtiκ
>
-[2,3-C]-pyran-3-yl) ketone;
(1'S,1R,3S) methyl-H2',3',6'-trideoxy-3'-triflιx»oa∞t_uriάo-4
<
-4ιydroxy-L- lyxc*c«cφyranoβe)-5,10-dioxo-3,4,5,10-tetπ_hydιo-7-ιnethyl-9-aza naphύio [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) medιyl(H2 3\6
,
-trideoxy-3
,
-triflι_oroacetamido-4
,
-hydroxy-L- lyxohexoρyranose)-5,10^iioxo-3,4,5,10-tetrahydro-7-ιnedιyl-9-aza naphtho [2,3-C] pyran-3-yl) ketone; (1'S,1R,3R) -H2\6
,
-dideoxy-L-lyxohexopyranoβe)-5,10-
<
lιoxo-3,4,5,10- tet ahydronaphtho [2,3-C] pyran;
(1'S,1S,3S) -l-(2',6
,
-didcoxy-L-lyxohexopyraDθβe)-5,10-dioxo-3,4,5,10- tetrahydrooaphύio [2,3-C] pyran;
(l'S, 1R,3R) -l-(2' ,3 ' ,6'-trideoxy-3 
•
-βmino-L-lyxohexopyranoβe)-5, 10-dioxo-3-etiiyl- 3,4,5, 10-tetrahydronaphtho [2,3-C] pyran;
(1'S,1S,3S) -l-(2 3\6
,
-trideoxy-3
,
-βmino-L-lyxohexopyranoβe)-5,10-dioxo-3-edιyl-
3,4,5, 10-tetιahydronaphdιo [2,3-C] pyran;
(1'S,1R,3R) -H2\3\6'-trideoxy-3'-aιnino- -lyxohexopyranoβe)-5,10-dioxo-6 or 9- hydroxy -3-ethyl-3,4,5,10-tetrahydronaphdιo [2,3-C] pyran; (1'S,1S,3S) -l-(2\3\6'-trideoxy-3'-amino-L-lyxohexopyιanoβe)-5,10-dioxo-6 or 9- hydroxy -3-ethyl-3,4,5,10-tetιahydrooaphUιo [2,3-C]
 pyran;
(1'S,1R,3R) -l-
<
2',3 6'-trideoxy-3'-«mino-L-lyxohexopyranoβe)-5,10-dioxo-6, 9- dihydroxy -3-ethyl-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran;
(1'S,1S,3S) -l-(2',3',6'-trideoxy-3'-amino-L^yxohexopyranoβe)-5,10-dioxo-6, 9- dihydroxy -3-ethyl-3,4,5, lO-tetnhydπMuφhtho [2,3-C] pyran;
(1'S,1R,3R) -l-(2',3',6'-trideoxy-3'- amino-2'-iodo-L-lyxcdιexopyranoβe)-5,10-dioxo-6 or 9-hydroxy -3-ethyl-3,4,5,10-tetrahydronaphdκ
>
 [2,3-C] pyran;
(1'S,1S,3S) -l-(2',3',6'-trideoxy-3'- amino-2'-iodo-L-lyxohexopyranoβe)-5,10-dioxo-6 or 9-hydroxy -3-ethyl-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran; (1'S,1R,3R) -l-(2 3\6
,
-trideoxy-3'-trifluoroaMtomido-L-lyxohexcφyranose)-5,10- dioxo-6 or 9-hydroxy -3-ethyl-3,4,5,10-tetrahydronaphtho [2,3-C] pyran;
(l'S, 1S,3S) -H2' ,3 ' ,6'-trideoxy-3 '-trifiuoιoacetamido-L-lyxohexopyranose)-5, 10- dioxo-6 or 9-hydroxy -3-ethyl-3,4,5,10-tetrahydronaphtho [2,3-C] pyran;
(1'S,1R,3S) Mediyl(H2\3\6'-tridcoxy-3'-amino-2
,
-iodo-L-lyxohex(^yr_u
1
ose)-5,10-
247
SUBSTITUTE SHEET 


 dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; (1'S,1S,3R) MediyKl-^'.S e'-trideoxy-S'-amino-Σ'-iαto-L-lyxcAexcφyianose)^.!©- dioxo-6 or 9-hydroxy-3 ,4,5, 10-tetrahydronaphtho [2,3-C]
 pyran-3-yl) ketone; (1'S,1R,3S) Memyl(H2 3\6'-trideoxy-3
,
-
<
mino-L-lyxcAexcφyranoβe)-5,10-dioxo-6 or 9-hydroxy-3,4,S, 10-tetrahydronaphflιo [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) Medιyl(l-(2',3',6'-trideoxy-3'-aιmno-I^lyxcdιexcφyιanoβe)-5,10-dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; (1'S,1R,3S) Medιyl(l-(2\3 6'-trideoxy-3
,
-βmiικ
>
-L-lyxohex(φyranoβe)-5,10-dioxo-6, 9-dihydroxy-3,4,5, 10-tetnhydrooaphtho [2,3-C] pyran-3-yl) ketone; (1'S,1S,3R) Methyl(l-(2',3',6'-trid∞xy-3'-amino-I^lyxohexcφynιιcm
9-dihydroxy-3,4,5,10-tetrahydronaphUιo [2,3-C] pyran-3-yl) ketone; (l'S, 1R,3S) Methyl(H2' ,3' ,6*-trideoxy-3*-triflι»ιoa_»taιriA -L-lyxcAexcφyranoβe)- 5, lO-dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C]
 pyran-3-yl) ketone; (1 'S, 1S.3R) Methyl(l-(2' ,3 ' ,6'-trideoxy-3 '-trifluoroacetamido-L-lyxohexopynnose)- 5, 10-dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone;
(l'S, 1R,3S) Methyl(l-(2' ,3 ' ,6'-trideoxy-3 '-trifluoroacetairido-L-lyxohexopyianose)- 5,10-dioxo-6, 9-dihydroxy-3,4,5,10-tetrahydronaphdιo [2,3-C] pyran-3-yl) ketone; (1'S,1S,3R) Medιyl(l-(2\3\6
,
-trideoxy-3'-triflιιoroacetamido-I^lyxohexopyrano8e)- 5,10-dioxo-6, 9-dihydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; (1'S,1R,3S) Methy H∑'.S'.β'-trideoxy-S'-βmino or trifluoroacetamido-2'-iodo-L- lyxohexopyranoβe)-5,10-dioxo-3,4,5,10-tetrahydπmaphUιo [2,3-C]
 pyran-3-yl) ketone; (1'S,1S,3R) Medιyl(l-(2',3',6'-trideoxy-3'-amino or trifluoroacetamido-2'-iodo-L- lyxohexcφyranose)-5,10-dioxo-3,4,5,10-tetr__hydronaphdιo [2,3-C] pyran-3-yl) ketone; (1'S,1R,3R) MeύiyKl-^'^ β'-trideoxy-S'-amino or trifluoroacetamido-2
,
-iodo-L- lyxohexopyranoβe 5,10-dioxo-3-edιyl-3,4,5,10-tetrahydrona}Adιo [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3S) Medιyl(l-(2',3',6'-trideoxy-3'-amino or trifluoroacetamido-2'-iodo-L- lyxohexopyranose)-5,10-dioxo-3-ethyl-3,4,5,10-tetrahydrona didio [2,3-C] pyran-3-yl) ketone; (l'S,lS,3R)-l-(2',3',6'-triά∞xy-3
,
-aminc
>
-UyxcAexcφynnc_βe)-3 2-az_ι-3- aminothia2θlyl)-5,10-dioxo-3,4,5,10-tetrahydro-lH-naphdιo [2,3-C] pyran; (l'S,lR,3S)-l-(2\3\6'-trideoxy-3'-amino-L-lyxohexopyιano__e)-3-(2-aza-3- aminothiazolyl)-5,10-dioxo-3,4,5,10-tetrahydro-lH-ιuφhUιo [2,3-C]
 pyran
31. A compound according to claim 1 selected firom the groiφ consisting of
Methyl (5,10-dioxo-3,4,5,10-tetrahydronaphdio [2,3-C] pyran-3-yl) ketone (BCH- 1125);
248
SUBS i f UTt SHEET 


 Methyl (7-hydroxy-5,10-dioxo-3,4,5,10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone (BCH-1129);
Methyl (6-hydroxy-5,10-dioxo-3,4,5,10-tetrahydronaphdιo [2,3-C] pyπn-3-yl) ketone; Monofluoromethyl (5,10-dioxo-3,4,5,10-t_ rahydronaphtho [2,3-C]
 pyran-3-yl) ketone; Brornoinediyl (5,10-rioxo-5,10-dihydronaιΛdιo [2,3-C] pyran-3-yl) ketone;
2-[4,-Hydroxy-r,2',-dioxo-3'- cyclobutenoxy] methyl (5,10- dioxo-3,4,5, 10- tetrahydronaphtho [2,3-C]
 pyιan-3-yl) ketone;
Trans-3-sceto-l-methoxy-l,2,3,4-tetrahydιo-(2-thia)anthracene-5, 10-dione and ciβ-3- a«»to-l-metboxy-l,2,3,4-tetπdιydro-(2-thia)anduacene-5, 10-dione; cis-3-aceto-l-methoxy-l,2,3,4-tetrahydro-(2-dιia) anthracene-5, 10-dione and trans-3-aceto-l-medioxy-l,2,3,4-tetrahydro-(2-thia) anthracene-5, 10-dione; (l'S,lS,3R)-l-(2 3\6'-trideoxy-3'-amino-L-lyxohexopyranoβe)-3-(2-aza-3- aminodιiazolyl)-5,10-dioxo-3,4,5,10-tetrahydro-lH-naphdιo [2,3-C] pyran; (l'S,lR,3S)-l-(2\3\6'-trideoxy-3'-amino-L-lyxohexopyranoβe)-3-(2-aza-3- aminodiiazolyl)-5,10-dioxo-3,4,5,10-tetrahydro-
lH-naphtho [2,3-C] pyran
32. A compound according to claim 1 aelected firom the group consisting of
Mediyl (l-hydroxy-5,10-dioxo-3,4,5,10-tetrahydromφhtho [2,3-C] pyran-3-yl) ketone (BCH-1148); tians-3-aceto-l-hydroxy-l,2,3,4-tetrahydro-(2-thia) anthracene-5, 10-dione and ciβ-3- aceto-14ιydroxy-l,2,3,4-tetπ_hydro-(2-dιia) anthracene-5, 10-dione;
33. . A compound according to claim 1 selected firom the group consisting of
1'S,1S,3R mediyl (5,8-dioxo-l-(2 3\6
,
-tridTOxy-3*-trifluoroacetamido-L-4
,
-0-p- ritrobenzoyl-L-lyxohexopyrano8e)-3,4,5,10- tetrahydrobenzo [2,3-C] pyran-3-yl) ketone;
1'S,1R,3S methyl (5,8-dioxo-K2',3',6'-trideoxy-3'-trifluoroaceta_ do-L-4'-0-^ ritrobenzoyl-___Λlyxc excφyιaιιoβe)-3,4,5,10-tetπιhydrobenzo [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) methyl (5,8-dimethoxy-l-
<
2\3\4\6'-tetπ_deoxy-3
,
4
,
- liacetoxy-L- Lyxohaxo-pyranose)-3,4,-dihydrobenzo [2,3-C] thiopyran-3-yl);
(1'S,1R,3S) methyl (5, 8-dimethoxy- H2\3\4\6' -tetradTOxy-3', 4' - lιacctoxy-L- Lyxohexopyranoβe)-3,4,-dihydrobenzo [2,3-C] thiopyran-3-yl); (1'S,1S,3R) methyl (5,8-dimethoxy-H2\3\4\6'-tctradeoxy-3',4'- iι_icetoxy- -lyxohexopyιanose)-3,4,-dihydrobenzo [2,3-C]
 thiopyran-3-yl) ketone; (1'S,1R,3S) methyl (S.β-dimethoxy-l^'.S'^'.β'-tetradeoxy-S'^'-diacetoxy-
L-lyxohexopyranose)-3,4,5,8, tetrahydrobenzo [2,3-C] thiopyran-3-yl) ketone;
34. A conφound according to claim 1 selected from the groiφ consisting of l'S, IS, 3R- Mediyl (5,10-dioxo-l-(2\3 6'-trid_Mxy-3
,
-trifluoroacetamido-4
,
O-p-
249
SUBSTITUTE SHEET 


 ritrobenzoyl-L-lyxohexcφyιanoβe)-3,4,5,10-tetπ_hydrona]riιtho [2,3-C]
 pyran-3-yl) ketone; l'S, IR, 3S- Mediyl (5,10-dioxo-l-(2\3\6'-trideoxy-3
,
-trifluoroacetamido-4
,
O-p- ritrobenzoyl-L-lyxohexopyranoβe)-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S Methyl (5,10κϋoxo-l-
<
2\3\6
,
-trid_»xy-3'-trifluoro«»tMri(k
>
-4
,
-0-p- ritrobenzoyl-L-lyxohexcφyranoβe)-7-hydroxy-3,4,5,10-tetrahydronaιAdιo [2,3-C] pyran-3-yl) ketone; l'S, IS, 3R Methyl (5,10-dioxo-l-(2\3 6
,
-trideoxy-3
,
-trifluoroa___etairick 4
,
-0-p- ritrobenzoyl-L-lyxohexopyranoβe)-7-hydroxy - 3,4,5, 10-tetnhydronaphUιo [2,3-C] ρyran-3-yl) ketone;
(1 'S,lS,3R)-BromomeUιyl (5, 10-dioxo-l-(2',3 ' ,6'-trideoxy-4'-0-P-nitrobenzoyl-3 '- trifluoroβcetamido-L-lyxohexopyranc_βeH3,4,5,10-tetιahydronaphdιo [2,3-C] pyran-3- yl) ketone; (l*S,lR,3S)-Bromomedιyl (5,10*Uoxo-H2',3',6'-trideoxy-4'-O-P-ritrobenzoyl-3'- trifluoroarotamido-L-lyxohexopyranose)-(3,4,5, 10-tetrahydronaphtho [2,3-C]
 pyran-3- yl) ketone;
(1'S,1S,3R) -Σ-K'-hydroxy-l'^'-dioxo-S'-cyclobutenoxy] mediyl (5,10-dioxo-l-
[2*,3*,6*-trideoxy-4'-Q-φ-ritipbenrayl-3'-trifluoroa^ 3,4,5, 10-tetrahydronaphtho [2,3,C] pynn-3-yl) ketone;
(1'S,1R,3S) -2-{4
,
-hydroxy-l',2'-dioxo-3
,
-cyclobutenoxy] mediyl (5,10-dioxo-l-
[2 3 6"-trideoxy-4
*
"-0-p-rit_robenzoyl-3'-trifluoroa_»tamiα^
3,4,5, lCMetnhydronaphύio [2,3, C] pyran-3-yl) ketone;
(1 'S,lR,3S)-l-(2' »3 ' .β'-trideoxy^'-O-p-ritrobenzoyl-S '-trifluoroacetamido-L- lyxohexopyranoβe)-3-(2-bromoacetyl)-5, 10-dioxo-3,4,5, 10-tetrahydro-lH-naphtho-
[2,3-C]-pynn;
(l'S, IR, 3S)-l-(2 3\6'-trideoxy-4
,
- p-ritrobenzoyl-3
,
-trifluoroa__»tamido-L- lyxohexopyranoβe)-3-(2-aza-3-aminothiazolyl)-5, lO-dioxo-3,4,5, 10-tetnhydro-lH- mφhdιo-(2,3-C
>
pyran; (l'S,lR,3S)-l-(2',3',6'-trideoxy-3'-trifluoroa∞tamido-4'^nitrobenzoyl-L- lyxohexopyranose)-3-(2-aza-3-acetamidothiazolyl)-5, 10-dioxo-3,4,5, 10-tetrahydro-lH- naphtho-[2,3-Cj-py_ran;
(l'S,lS,3RH-(2\3
,
-6
,
-triά»xy-4'-p-ritrobeι__zoyl-3
,
-t^ lyxohexopyranose)-3-(2-bromoacetyl)-5,10-dioxo-3,4,5
^
 [2,3- C] pyran;
(l'S,lS,3R)-l-(2 3'-6'-trideoxy^
,
-αp-ritrobenzoyl-3'-trifluoroacetamido-L- lyxolιexopyranoβe)-3-(2-aza-3-acetaιrido)-5,10^oxo-3,4,5,10-tetrahydιo-lH^ιφhtho^
[2,3-C]-pyran;
(1'S,1R,3S) methyl (l-[2',3\6'-trideoxy-3'-trifluoιoacetamido-4'-Oi
>
-nitrobenzoyl-L-
250
C I I f
*
* C T
* r
 """- 
~ ~~~
-' -~ tr r r 
~
— 
~~
~ 
■
 Ub^ i 1 1 u ; c SHEc 


 lyxohexo-pyrano6e]-5,10-dioxo-3,4,5,10-tetrahydro-7-methyl-9-aza naphdio [2,3-C]
 pyπm-3-yl ketone;
(1'S,1S,3R) mediyl (l-[2',3',6'-trideoxy-3'-trifiuoroa∞tamido-4'-Oi
>
-ritrobenzoyl-L- lyxcAexo-pyr_moee]-5,10-dioxo-3,4,5,10-tetrahydro-7-methyl-9-aza naphtho [2,3-C]
 pyran-3-yl ketone;
(l'S,lR,3S)-m_Hhyl-l-(2
,
,6'-dideoxy-3',4'-di-Oφ-ritroben2oyl-L- lyxohexopyranose)-5, 10-dioxo-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone;
(l'S, lS,3R)-methyl-l-(2' ,6'-dideoxy-3 ' ,4'-di-0-p-ritrobenzoyl-L-lyxohexopyranoee
>
- 5, lO-dioxo-3,4,5, 10-tetiahydronaphtho [2,3-C] pyτan-3-yl) ketone;
(l'S, IR, 3R
>
5,10-dfoxo-3-ethyl-lK2',3',4',6'-tetndeoxy-3 4'-diacetoxy- - lyxohexopyranoβe)-3,4,5,10-tetιahydro-lH-naphdιo [2,3-C] pyran; (l'S, IS, 3S)-5,10-rioxo-3-ethyl-l-(2',3
,
,4',6'-tetradeoxy-3',4
,
-diacetoxy-L- lyxohexopyranoβe)-3,4,5,10-tetrahydro-lH-naphdιo [2,3-C] pyran; (1*S,1S,3R) methyl (5,8-dioxo-l-(2',3', 4',6'-tetradeoxy-3\4'-diacetoxy-L- lyxohexoρyranoβe)-3,4,5, 10-tetrahydronaphtho [2,3-C]
 thiopyran-3-yl) ketone; (1'S,1R,3S) methyl (5,8-dioxo-l-(2',3', 4*,6'-tetradeoxy-3',4
,
-diacetoxy-L- lyxohexopyranoβe)-3,4,5, 10-tetrahydronaphtho [2,3-C] thiopyran-3-yl) ketone;
35. A compound according to claim 1 selected from the group consisting of l'S, IR, 3S Methyl (S^Cl-dioxo-l^'^'.β'-trideoxy-S'-trifluoioacetamido^'-hydroxy-
L-lyxohexopyranoβe)-3 ,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S Methyl (5,l()-dioxc
>
-l-(2 3
,
,6'-trideoxy-3
,
-amiικ 
,
-4ιydroxy-L- lyxobexopyranoβe)-3,4,5, 10-tetrahydronaphtiιo [2,3-C] pyran-3-yl) ketone; l'S, IS, 3R Methyl (5,10-dioxo-H2\3 6'-trid_»xy-3^Triflικ
>
ιt)ace ιnido-4'- hydroxy-L-lyxobexopyranoβe)- 3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; l'S, IS, 3R Mediyl (5,10-dfoxo-H2',3',6'-αid∞xy-3'-amiιιo-4'^ιydroxy-L- lyxohexoρyraooee)-3,4,5, 10-tetrahydronaphtho [2,3-C]
 ρyιan-3-yl) ketone; l'S, IR, 3S Mediyl (5,10^foxo-l-(?',3',6'-tήdeoxy-3'-trifiuoroacetamidc
>
-L- lyxohexopyranoβe)-7-hydroxy - 3,4,5, 10-tetrahydro [2,3-C] pyran-3-yl) ketone; l'S, IR, 3S Methyl (5,10-dioxo-l-(2',3',6'-trideoxy-3'- amino-L-lyxohexopyranoβe)-7- hydroxy-3,4,5, 10-tetrahydro [2,3-C]
 pyran-3-yl) ketone;
(1'S,1S,3R) mediyl (5,10-dioxo-l-(2',3 6
,
-trideoxy-3'-trifiuoroacetamido-L- lyxohexopyranose)-7-hydroxy - 3,4,5,10-tetrahydro [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) mediyl (5,10-dioxo-l-(2',3',6'-trideoxy-3'- amino-L-lyxohexopyτanose)-7- hydroxy- 3,4,5,10- tetrahydro [2,3-C] pyran-3-yl) ketone;
(l'S,lR,3S)-l-(2\3\6
,
-trideoxy-3
,
-trifluoroacetamido-L-lyxohexopyranose)-3-(2-aza-
3-acetamidodιiazolyl)-5,10-dioxo-3,4,5,10-tetrahydro-lH-naphtho [2,3-C] pyran;
251
SUBSTIT U . 5πcι 


 (l'S, lR,3S)-l-(2' ,3 ' ,6'-trideoxy-3 '-trifluoroacet_u do-L-lyxohexopyτanose)-3-(2-aza-
3-acetamidothiazol)-5, lO-dioxo-3,4,5, 10-tetτahydro-lH-naphtho [2,3-C]
 pyran;
(1 'S, lS.SR^H∑'.S 6'-trideoxy-3 '-trifluoroacetanύdo-L-lyxohexopyranose -S^-aza-
3-acetamido- thiazolyl)-5, 10-dioxo-3,4,5, 10-tetrahydιo-lH-naphtiιo-[2,3-C]-pyιan; (l'S.lS.SRVl^SS'.β'-trideoxy-S'-trifluoroacetamid^L-lyxohexopyranose^^-aza^
3-aminodιiazolyl)-5, 10-dioxo-3,4,5, 10-tetnhydro-lH-naphtiio-[2,3-C]-pyian;
(1'S,1R,3S) Methy l^'^'.β'-trideoxy-S'-βmino-L-lyxohexopyranose^S.lO-dioxo-
3,4,5, 10-t__
<
rahydro-7-mediyl-9-a7anaphtho-[2,3-C]-pyran-3-yl) ketone;
(1'S,1S,3R) Mediy H∑'.S'.β'-trideoxy-S'-amino-L-lyxohexopyranoβeVS.lO-dioxo- 3,4,5, 10-tetιahyάjt
>
-7-methyl-9-azanaphdκ)-[2,3-C] )yιan-3-yl) ketone;
(1'S,1R,3S) medιyl-l-(2\3\6'-trideoxy-3'-trifluoroacetamick
>
-4' ιydroxy-L- lyxohexopyranoβe)-5,10^iioxo-3,4,5,10-tetrahydπ
>
-7-methyl-9-aza naphdio [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) metiiyKH∑'.S'.β'-trideoxy-S'-trifluoroacetairidcHi'-hydroxy-L- lyxc^xcφyr_moβe
>
5,10-rioxo-3,4,5,10-tetrahydro-7-methyl-9-aza naphtho [2,3-C] pyran-3-yl) ketone;
36. A compound according to claim 1 aelected from the group consisting of
(1 'S, 1R,3R) -l-(2',6'-dideoxy-L-lyxohexopyranoβe)-5, 10-dioxo-3,4,5, 10- tetrahydronaphdio [2,3-C] pyran;
(1'S,1S,3S) -H2',6'-dideoxy-L-lyxohexopyniio8e)-5,l(Mioxo-3,4,5,10- tetrahydronaphtho [2,3-C] pyran;
(l'S, 1R.3R) -l-(2
*
,3 ' .β'-trideoxy-S'-amino-L-lyxohexopyranoβe)^, 10-dioxo-3-ethyl-
3,4,5,10-tetnhydroιuφhtho [2,3-C] pyran; (1'S,1S,3S) -l-(2
,
,3',6
,
-trideoxy-3'-ammo-L-lyxohexopyranose)-5,10-dioxo-3-edιyl-
3,4,5, 10-tetrahydronaphύιo [2,3-C] pyran;
(1'S,1R,3R) -H2',3',6'-trideoxy-3'-amino-L-lyxohexopyranose)-5,lθ-dioxo-6 or 9- hydroxy -3-ethyl-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran;
(1'S,1S,3S) -H2 3 6'-trideoxy-3
,
-amin
<
>
-L-lyxohexopyranoee)-5,10-dioxo-6 or 9- hydroxy -3-edιyl-3,4,5,10-tetrahydronaphtiιo [2,3-C] pyran;
(1'S,1R,3R) -l-(2',3\6
,
-trideoxy-3'-amino-L-lyxohexcφyranose)-5,10-dioxo-6, 9- dihydroxy -3-ethyl-3,4,5,10-tetrahydronaphdιo [2,3-C] pyran;
(1'S,1S,3S) -l-(2 3\6'-triάeoxy-3'-amino-L-lyxohexopyιanose)-5,10-dioxo- , 9- dihydroxy -3-ethyl-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran; (1'S,1R,3R) -H∑'.S'.β'-trideoxy-S'- amino-2
,
-iodo-L-lyxohexopyranose)-5,10-dioxo-6 or 9-hydroxy -3-ethyl-3,4,5,10-tet_rahydronaphUιo [2,3-C] pyran;
(1 *S, 1S.3S) -H2' ,3 ' ,6'-trideoxy-3 '- amino-2
,
-iodo-L-lyxohexopyranoβe)-5, 10-dioxo-6 or 9-hydroxy -3-ethyl-3 ,4,5, 10-tetrahydronaphtho [2,3-C] pyran;
(1'S,1R,3R) -H2\3\6'-trideoxy-3'-trifluoroacetamido-L-lyxohexopyranose)-5,10-
252
SUBSTITUTE SHEET 


 dioxo-6 or 9-hydroxy -3-ethyl-3, 4,5, 10-tetrahydronaphtho [2,3-C] pyran; (1'S,1S,3S) -l-(2\3\6'-triά^xy-3'-trifluoroacetaπιido-L-lyxohexopyranose)-5,10- dioxo-6 or 9-hydroxy -3-ethyl-3,4,5, 10-tetrahydronaphtho [2,3-C]
 pyran; (1'S,1R,3S) Methyl(H2',3',6
,
-trid^xy-3
,
-amino-2
,
-iodo-L-lyxohexopyιanose)-5,10- dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphdιo [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) Mediy H∑'.S'.β'-tridwxy-S'Hurino-Σ'-iodo-L-lyxohexcφyranose^S.lO- dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; (1'S,1R,3S) Methyl(l-(2',3',6'-trideoxy-3'-aιrino-L-lyxohexcφyπuιose)-5,10-dioxo-6 or 9-hydroxy-3,4,5,10-tetrahydronaphdιo [2,3-C]
 pyran-3-yl) ketone; (1'S,1S,3R) Medιyl(l-(2',3',6
,
-trideoxy-3'-amino-L-lyxohexcφynnose)-5,10-dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; (l'S, 1R,3S) Methyl(l-(2' ,3 ' ,6'-trideoxy-3*-amino-L-lyxohexopyranose)-5, 10-dioxo-6, 9-dihydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C]
 pyran-3-yl) ketone; (1'S,1S,3R) Methyl(H2\3\6'-trid_»xy-3'-aminc)-L-lyxohexopyrano__e)-5,10-dioxo-6
(
 9-dihydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone;
(1'S,1R,3S) Memyl(l-(2\3\6
,
-trideoxy-3'-trifluoroacetamido-L-lyxohexopyranose)- 5,10-dioxo-6 or 9-hydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; (1'S,1S,3R) Meuιyl(l 2',3
,
,6
,
-trideoxy-3'-trifluoro_κxstaιrido-L-lyxohexopyr_moβe 5,10-dioxo-6 or 9-hydroxy-3,4,5,10-tetrahydro__taphtho [2,3-C] pyran-3-yl) ketone; (1'S,1R,3S) Meώyl(l-(2\3\6
*
-trid^xy-3
,
-trifluoroaM
>
tamido-L-lyxohexopyranoβe)-
5,10-dioxo-6, 9-dihydroxy-3 ,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone; (1'S,1S,3R) Medιyl(l-(2\3 6'-trideoxy-3'-trifiuoroacetamido-L-lyxohexopyranose)- 5,10-dioxo-6, 9-dihydroxy-3,4,5, 10-tetrahydronaphtho [2,3-C]
 pyran-3-yl) ketone; (1'S,1R,3S) Methy l^'.S'^'-trideoxy-S'-amino or trifluoroacetamido-2'-iodo-L- lyxohexoρyranoβe)-5, lO-dioxo-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone;
(1'S,1S,3R) Medιyl(l-(2\3\6
'
-trideoxy-3
,
-amino or trifiuoroacetamido-2
,
-iodo-L- lyxohexopyranoβe)-5,10-dioxo-3,4,5,10-tetπ_hydronaphdιo [2,3-C] pyιan-3-yl) ketone; (1'S,1R,3R) Meuiy l^'^'.δ'-tiideoxy-S'-amino or trifluoroacetamido-2'-iodo-L- lyxohexopyrano_«)-5,10-rioxo-3-ethyl-3,4,5,10-tetrahydronaphdιo [2,3-C]
 pyran-3-yl) ketone;
(1'S,1S,3S) MethyKl^'^'.e'-trideoxy-S'-amino or trifluoroacetamido-2'-iodo-L- lyxohexopynnoβe)-5,10-dioxo-3-ethyl-3,4,5, 10-tetrahydronaphtho [2,3-C] pyran-3-yl) ketone;
(1 *S, lS,3R)-l-(2' ,3' ,6'-trideoxy-3 '-amino-L-lyxohexopyranose)-3-(2-aza-3- aminodύazolyl)-5,10-dioxo-3,4,5,10-tetιahydro-lH-4_aphdιo [2,3-C] pyran;
(l'S, 1R,3S)-H2' ,3 ' ,6'-trideoxy-3 '-amino-L-lyxohexopyιanose)-3-(2-aza-3- amim)thiazolyl)-5,10-dioxo-3,4,5,10-tetrahydrc)-lH-naphtho [2,3-C] pyran;
37. A compound according to Claim 1 selected firom the group consisting of:
253
SUBSTITUTE SHEET 


 1184 (l 'S, IS, 3R)-methyl-(l-[2 ' ,3 ' , 6 ' -tridβoxy-3 ' - trif luoro-acβtamido- 
■
 -hydroxy-L-lyxohexo-pyranoβe]- 3,4, 5, 10-tβtrahydro-naphtho[2,3-C]
pyran-3-yl)ketone
1620 (l'S,l-R,3-S)-meώyl-(l-[2
,
,3
,
,6
,
-trid_∞xy-3'-trifluoroac^^ lyxohexopyranose)-5,10-cUoxc
>
-3,4,5,10-tetrahydronaphdιc_-[2,3-C]pyr_uι-3-yl)ketone
1648 (l'-S.l-S^-R^inethyHl-B'.S'.β'-trideoxy-S'-trifluoroai-Λtamido^'-hydroxy- L-arabmc
>
-hexcφyrBnose)-5,10-rioxo-3,4,5,10-tetrahydroιuφhtbo-[2,3-C]pyran-3- yl)ketone
1649 (1 '-S, l-R,3-S)-medιyl-(l-[2
,
,3 ' ,6'-trideoxy-3 '-trifluoroacetamido^'-hydroxy- L-arabino-hexopyranoGe)-5, 10-dioxo-3,4,5, 10-tetrahydronaphtho-[2,3-C]pyran-3- yl)ketone
1666 (l'S,lR,3S)-methyl-(l-[2',6'-dideoxy-3
,
,4
,
-diacetyl-2
,
Hθdo-L- lyxohexopyranose]-3 ,4,5, 10-tetrahydron_φhtho[2,3-C]
pyran-3-yl) ketone
1667 (l'S, IS, SR^methyKU∑'.β'-dideoxy-S'^'-diacetyl^'-iodo-L- lyxohexopyranose]-3,4,5,10-tetrahydronaphtho[2,3-C]
pyran-3-yl) ketone
1673 (l
,
-S,l-S,3-R) aIld (l
,
-S,l-R,3-S)-IIleώyKl-[2
,
,3 4 6
•
-tetradeoxy-4
,
- trifluoroacetaιrido-L-lyxohexopyιanose)-5,10-rioxo-3,4,5,10-tetrahydroιuφhtho-[2,3-C ]pyran-3-yl)ketone
1998 (lS,3S,2'S,5'S)-medιyl-(l-0-tN-Boc-βerine-leucine-me ester]-5,10-dioxo- 3,4,5, 10-tetrahydronaphUιaleno-[2,3-C]
pyran-3-yl)ketcme
2000 (lS,3S,2'S,5'S)-methyHl-0-[sαine-leucine-ιne ester]
-5, lO-dioxo-3,4,5, 10- tetrahydron__φhtfaaleno-[2,3-C]pyran-3-yl)ketone hydrochloride
2019 

L-lyxohexopyranose]-5,10-rioxo-3,4,5,10-tetrahydrcm^ithaleno-[2,3-C]
pyran-3- yl)ketone
2022 (l'S,lS,3R)-IIlethyl-(l-[2
•
,3
•
,6
,
-trideoxy-4
•
-hydroxy-2
,
-iodo-3
,
- trifluoroacetaιrido-L-lyxohexopyιaικ
>
se]-5,10H__ioxo-3,4,5,10-tetrahydiOi___φhtho[2,3,-C
]pyran-3-yl)ketone
254
_r* i ■ -* f ~~~
m
 ~ ~~~" ~ i ~~~- ~~~ ~~~ ~ 9 ~-~ ~-~ T" cT 


2041 phenyHtrans-l-πι_sdιoxy-5,10-dioxo-3,4,5,10-tetπ_hydro-lH-na}Λtho-f2,3-C]- pyran)-3-carboxamide

 L-lyxohexopyιanose]-5, 10-dioxo-3,4,5, 10-tetrahydronaphthaleno-[2,3-C]
pyran-3- yl)ketone
2047 (lS,3R,l'S
>
methyHl-[2 3\4\6
,
-tetradeoxy-3'-trifluoroacetaιrido-4
,
-broπιo
τ
 L-lyxohexopyranose]-5, lO-dioxo-3 ,4,5, 10-tetranaphthaleno-[2,3-C]
pyran-3-yl)ketone .
2051 3-dimethylaminopropyla(l-medιoxy-5, 10-dihydro-lH-naphtho-[2,3-C]-pyran)- 3-carboxamide
2061 (1S,2'S,3R) and (lR,2'S,3S)-methyl-(l-O-[3-pipecolinemedιanol]-5,10-dioxo- 3,4,5,10-tetrahydronaphdialeno-[2,3-C]
pyran-3-yl) ketone hydrochloride racemic mixture
2069 methyl-
<
l-O-[4-pipecolinemethanol]-5,10-dioxo-3,4,5,10- tet_rahydronaphthaleno-[2,3-C]
pyran-3-yl)ketone hydrochloride racemic mixture
2070 (V-S,l-R,3-Symem-.y l-[2',y,4',6' tetrad__oxy-3'-methoxy-4'-0- methanesrifcmyl-L-lyxc^xcφyranoβe)-5,10-rioxo-3,4,5,10-tetιahydr(maphth pyran-3-yl)ketone
2071 (l'-S,l-S,3^)-m_Λyl-
<
l-[2',3\4\6
,
-tetradeoxy-3
,
,4'-dimethoxy-I,- lyxohexopyranose)-5, 10-DIOXO-3,4,5, 10-tetrahydronaphtho-[2,3-C]pyran-3-yl) ketone (Tentative assignment)
2072 (l'-S,l-R,3-R)-methyl-l-[2
,
,3',4
,
,6
,
-tetradeoxy-3
,
-m«_thoxy-4'0- methanesulfonyl-L-lyxobexopyranose)-5, 10-dioxo-3,4,5, 10-tetrahydronaphtho-2,3-C]- pyran-3-yl-ketone
2079 (lS,l'S,3RO-methyHl-[2 3
,
,4\6
,
-tetradeoxy-4
,
-trifluoroacetamido-L- lyxohexopyranose]-5, lO-dioxo-3,4,5, 10-tetrahydronaphthaleno-[2,3-C)pyran-3- yl)ketone
2087 (1R,3S,1'S) and (lS,3R,l'S)-METHι 
<
l-[2
,
,3',4\6
,
,-tetra^ bistrifluoroacetaιmdo-lyxo-hexopyranose]-5,10-dioxo-3,4,5,10-tetι^ydro-n_φhth^
[2,3-C]pyran-3-yl)ketone
255
SUBSϊi.ϊJTc SHEET 


 2095 (l'-S,l-S,3-R) and (l'S,l-R,3-S)-methyl-(H2
,
,3
,
,4
,
,6
,
-tetrad^^ triflιirt
T
vuι _^nm;_^ _ '- __.nv»lh_ιn_»gιι1fnn l-T _-lyτnpyτanmM-)-5
r
 IO-dinτθ-3.4.5.10- tetrahydronaphtho-[2,3-C)pyran-3-yl)ketone
2102 (1S,3R, 1 
,
S)-Inedlyl-(l-[2
•
 ,3 ' ,4' ,6-tetradeoxy-3 ' ,4'-bistrifluoroacetamido-lyxo- hexopyranose]-5,10-rioxo-3,4,5,10-tetrahydronaphdιaleno-[2,3-C]
pyran-3-yl)ketone
2104 (lR,3S,l'S)-ιι_ethyl-(l-[2 3 4 6-tetradeoxy-3\4
,
-bistrifluoιoacetaιnido-lyxo- hexopyπnose]-5, lO-dioxo-3,4,5, 10-tetrahydronaphthaleno-[2,3-C]
pyτan-3-yl) ketone
2105 (l'-S,l-S,3-R)-medιyl-(l-[2 3\4
,,
6
,
-tetradeoxy-3'-trifluoroacetamido-4'-0- (2-brorno-acetyl)-L-lyxopyranose]-5,10-rioxo-3,4,5,10-tetrahydronaphtho-[2,3-C]
 pyran-3-yl) ketone
2112 (1 'S, lR,3S)-i8oprcφyl-[l-(2
*
,3 ' ,6'-trideoxy-3 
,
-trifluoroacetamido-L- lyxt*excφyranoβe)-3,4,5,10-tetrahydro-lH-NAPHTO[2,3-C]-pyranyl]
ketone
2113 A 4:1 Misture of (l'S.lR.SSHnethyHl-P'.S'.e'-trideoxy-S'- trifluoroa∞taιrido-4-iodo-L-anb_no-hexopyranose)-5,10-dioxo-3,4,5,10- tetrahydronaphthcH2,3-C]pyian-3-yl)ketone and 



 trideoxy-3'-trifluoιoacetan_ido-4'-iodc
>
-beta-L-arabrio-h^^
3,4,5, 10-tetrahydronaphtho-[2,3-C}pyran-3-yl) ketone
2117 (l'S,lS,3R) and (l'S,lR,3S)-methyl-(l-[2
,
,6
,
-dideoxy-3
,
,4
,
-dihyd?oxy-L- lyxohexopyranose]-5, 10-dioxo-3,4,5, 10-tetrahydronaphtho[2,3-C]
-pyran-3-yl) ketone
2118 (1'S,1S,3R) and (l'S,lR,3S)-methyl-(l-[2',6'-dideoxy-3',4'-diacetoxy-L- lyxohexopyτanoβe]-5, 10-dioxo-3,4,5, 10-tetrahydronaphtho[2,3-C]
pyran-3-yl) ketone
2121 (l
,
S,lS,3R)-5,10-rioxo-3-isc I poxyca_rbonyl-l-(2
,
,3
,
,6
•
-trideoxy-3
,
- trifluoroav*amido-L-lyxohexopyranose 3,4,5,10-tetrahydro-lH-nφhtho[2,3-C]-py^
38. A coπφound according to Claim 1 selected from the group ccmsisting of:
1184 (l'S, IS, 3R)-methyl-{l-t2
,
,3
,
,6'-trideoxy-3
,
-trifluoroacetamido^'-hydroxy- L-lyxohexopyranose]-3,4,5, 10-tetrahydronaphtho[2,3-C]
pyran-3-yl) ketone
1620 (1 'S, l-R,3-S)-methyl-(l-[2\3\6'-trideoxy-3 '-trifluc McetamidcHl'-iodo-L-
256 c ι I Π TJ I ------- e- . - 
~
~
~
 ~
~
--τ- 


 lyxohexopyπuιoβe)-5,10-rioxo-3,4,5,10-tetrahydronaphtho-[2,3-C^
1648 (1 '-S, l-S.S-R^memyHl-β'.S'.β'-trideoxy-S'-trifluoroacetamido^'-hydroxy- L-arabiiK
>
-hexopyrano_»)-5,10-dioxo-3,4,5,10-tetrahydronaphtho-t2,3-C]pyran-3-yl) ketone
1169 (l'S, IR, 3S) AND (l'S, IS, SR^methyKl-CS'.β'-trideoxy-S'- trifluoroac^amido-4'-hydroxy-L-lyxohexopyranose3-7-hydroxy-3,4,5,10- tetrahydronaphthot2,3-C]pyran-3-yl) ketone

 lyxohexopyranose]-3,4,5, 10-tetrahydroιuφhtho[2,3-C]
pyran-3-yl) ketone
1667 (l'S, IS, SR^methyKlD'.β'-dideoxy-S'^'-diacetyl-Σ'-iodo-L- lyxo_uxopyrano∞]-3,4,5,10-tetrahydrona]
dιtho[2,3-C]pyran-3-yl) ketone
1673 (l'-S,l-S,3-R) and (l'-S,l-R,3-S)-methyl-(l-[2',3
,
,4',6'-tetradeoxy-4'- trifluoroacetamido-L-lyxohexopyranose)-5, 10-dioxo-3 ,4,5, 10-tetrahydronaphtho-[2,3-C ]pyran-3-yl) ketone
2019 (lR,3S,l'S0-metoyl-(l-[2
,
,3
,
,4\6
<
-t__4nd___oxy-3
,
-trifiuc Mcetaιri L-lyxohexopyranose]-5, 10-dioxo-3,4,5, 10-tetrahydro-naphthaleno-[2,3-C]
pyran-3-yl) ketone
2046 (lR,3S,l'S)-m_^yKl-[2
,
,3
,
,4
,
,6'-tetradeoxy-3'
L-lyxohexopyπnose]-5,10-dioxo-3,4,5,10-tetrahydrona}dιthaleno-[2,3-C]
pyιan-3-yl) ketone
2047 (lS,3R,l
,
S)-ιnedιyl-(l-t2\3\4 6
,
-tetradeoxy-3
,
-trifluoroa_»tamidc
>
-4'-bronκ
>
- L-lyxohexopyranose]-5,10-dioxo-3,4,5,10-tetranaphthaleno-[2,3-C]
pyran-3-yl) ketone
2051 3-dimethylaminopropyla(l-ιnethoxy-5, 10-dihydro-lH-naphtho-[2,3-C]-pyran)- 3-carboxamide
2061 (1S,2'S,3R) and (lR,2'S,3S)-m_^yl-(l-C^[3-pipecolmemethanol]-5,10-dioxo-
3,4,5, 10-tetrahydronaphthaleno-[2,3-C]pyran-3-yl) ketone hydrochloride racemic mixture
2070 (l
•
-S,l-R,3-S)-IIlethyl- l-[2
,
,3',4
,
,6
,
 tetradeoxy-3 
,
-methoxy-4'-0-
257
SUB^ N ι ϋ ; c ntcϊ 


 methanesrifonyl-L-lyxohexopyranose 5,10-rioxo-3,4,5,10-tetrahydronaphdιo-[2,3-C] pyran-3-yl) ketone
2071 (l'-S,l-S,3-4)-methyl-
<
l-[2\3\4\6
,
-tetπιdeoxy-3 4
,
-dimethoxy-L- lyxcAexcφyranose)-5,10-dioxo-3,4,5,10-tetrahydronaphtho-[2,3-C]pyran-3-yl) ketone
(TENTATIVE ASSIGNMENT)
2079 (lS,l'S,3RO-methyl-(l-[2 3',4\6
,
-tetrad_»xy-4
,
-triflucm)acetamidc
>
-L- lyxόhexopyranose]-5, 10-dioxo-3,4,5, 10-tetrahydronaphthaleno-[2,3-C]
pyran-3-yI) ketone
2087 (1R,3S,1'S) and (lS,3R,^S)-Inethyl-(l-[2
,
,3
•
,4
,
,6
,
,-tetradeoxy-3
,
,4
•
- bistrifluoroacetamido-lyxo-hexopyranose]-5, 10-dioxo-3,4,5, 10-tetιahydro-naphthaleno- [2,3-C]
pyran-3-yl) ketone
2105 (l
,
-S,l-S,3-R)-IIlethyl-(l-[2 3 4'
,
6
,
-tetradeoxy-3
,
- rifluoroacetaIrido^
,
^ (2-bromo-acetyl)-L-lyxopynno_»]-5,10-dioxo-3,4,5,10-tetnhydronaphtho-[2,3-C]
 pyran-3-yl) ketone
2117 (l'S,lS,3R) and (l'S,lR,3S)-ιnethyl-(l-[2',6
,
-dideoxy-3
,
,4
,
-dihydroxy-L- lyxohexo-pyr_urøβe]-5,10-dioxo-3,4,5,10-tetrahydrouqdιtho[2,3-C]
-pyran-3- y 1 ) ketone
39. A process for the preparation of a compound of foπnula ,
and pharmaceutically acceptable acid addition salts thereof wherein X3 is selected from the group consisting NR, 0, or S, Rg is methyl ketone or is as defined in claim 1; and R
j
, R
2
, R3, R5, Rg, R7, Rg, X
j
, X
2
 and X4 are as defined in claim 1 selected from die group of processes consisting of I. 1) selecting a precurser isochroman compound of formula
258
SUBSTITUTE SHEET 

wherein R5, Rg, R7 and Rg are defined as above, oxidatively demethylating said compound with an oxidant to give a quinone conφound of foπnula
15
2) and cycle-adding said quinone witii a diene of foπnula
wherein L is a leaving groiφ selected from the group consisting of halogen, tosyl, benzoyl, p-nitrobenzoyl and -OR or -SR, wherein R is selected from the group consisting of hydrogen, C
j
.
j
g alkyl, C
j
.
j
g acyl, C
j
.
j
g aryl, C
j
.
j
g alkylsilane and dimethylamino,
wherein R
j
, R
2
, R3 and X4 are as defined as above; to yield a tricyclic heteronaphthoquinone of foπnula

 and
3) optionally coupling said tricyclic heteronaphthoquinone at R5, wherein R5 is -OH, to
259
SUBSTITUTE SHEET 


a saccharide of foπnula
18a 18b
wherein R9, RJQ. RJI -~~- R
]
2 
ue
 defined as in claim 1 and L is as defined above; to yield a tricyclic saccharide of formula
π. a) coupling the isochroman (14) of reaction 1,1, above, wherein R5 is H, with a saccharide of formula
20
wherein R9, RJQ, RJJ and R
j2
 are defined as in claim 1 to yield a bicyclic saccharide of formula
21
b) oxidatively demethylating the medioxy groiφs from formula (21) to yield a bicyclic
260
SUBSTITUTE SHEET 


quinone saccharide of formula
19
c) and cyclo-adding said chemical (19) with said diene (16) of reaction (I)(2) to yield the tricyclic saccharide
m. 1) coupling the quinone of foπnula 15,
15
of step (I) (1), wherein R5 is -OH, with a saccharide of die formula
18a 18b
of step (I) (2) to yield a bicyclic quinone sacharide of the formria
261
SUBSTITUTE SHEET 

19
2) and cycloadding said quinone saccharide with the said diene of formula
16
to yield a tricyclic saccharide of formula
IV. a) selecting a precurser benzoate compound of formula
and condensing it witii a dihalomethyl dimethoxybenzene wherein said halogens are indepently selected from die groiφ consisting of Cl, Br and I, and X3 is selected from the group consisting of O,S, and N;
262
SUBSTITUTE SHEET 

to yield a dimethoxyisochroman of formria,
b) oxidatively demethylating the methoxy groups from formula 14 to a bicyclic dioxoisochroman; the resulting dioxoisochroman is cyclically coupled with the diene of formula

 16
A is NR wherein R is selected from the group consiting of H, C
j
.
j
g alkyl, C
7
.
j
g aryl and L is a leaving groiφ as defined in 1.2) to yield an anthracenedione of formula
the resritant ccmφound may optionally be ctmverted to die hydroxyl form of formria
263
SUBSTITUTE SHEET 

and may be optionally coupled with a saccharide of formria 20 to yield die tricycbc saccharide of formria 12;
V. a dimethoxyisothiochroman of formula
may be optionally coupled with a saccharide of formria

 0
1) to yield a dimethoxybicydic saccharide of formria
2) oxidatively demethylating the methoxy groups to yield a dioxobicycbc isochroman of formula
264 o Cu I It R 
■*
* 
■
i
■•*•■
t-
■ ■
 ft" n - tc 
f
rt
mm
Tr- 

3) cycloadding said dioxobicycbc isothiochroman with a diene of formula 29
to yield a thiotncycbc saccharide of formula.
40. Process according to claim 39 comprising the further preliminaiy steps of a:
a) reacting
or b)
265
SUBSTITUTE SHEET 

c) to yield product:
d) and further reacting said product:
with
L \ H Rs L — C -Rs \~/ H or c ^ *
to yield:
41. A process, according to claim 39, for the preparation of a coπφound of formula,
266
SUBSTITUTE SHEET 

and pharmaceutically acceptable acid addition salts thereof, wherein X3 is selected from the groiφ consisting of N, S, or 0, Rg is methyl ketone or is as defined in claim 4 and R
j
, R
2
, R3, R5, Rg, R7, Rg, and X4 are as defined in claim 4 which comprises the steps of I. 1) selecting a precurser isochroman coπφound of formula,
14
wherein R5, Rg, R7 and Rg are defined as above; oxidatively demethylating said isochroman with an oxidant to give a quinone compound of formula,
2) and cyclo-adding said quinone with a dime of formula,
wherein L is a leaving group selected from the group consisting of halogen, tosyl, benzoyl, p- nitrobenzoyl and -OR or -SR, wherein R is selected from the groiφ consisting of hydrogen C
j
. 
j
g alkyl, C
j
.
j
g acyl, and C
j
.
j
g aryl, C
j
.
j
g alkyl silane and dimethylamino;
267
SUBSTITUTE SHEET 


 wherein R
j
, R
2
, R3 and X4 are as defined as above; to yield a tricycbc heteronaphthoquinone of formria,
and
3) optionally coupling said tricycbc heteronaphthoquinone at R5, wherein R5 is OH, to a saccharide of formria,

 18a 18b
wherein R9, RJQ, RJJ and R
j2
 are defined as in claim 4 and L is a leaving group selected from the group consisting of halogen, benzoyl, tosyl, p-nitrobenzoyl and -OR or -SR, wherein R is selected from the group consisting of C
j
.
j
g alkyl, C
j
.
j
g acyl, C
j
.
j
g aryl, and C
j
. 
j
g trialkylsilane, to yield a tricycbc saccharide of formula,
42. A process according to claim 39 for the preparation of a compound of formula,
268
SUBSTITUTE SHEET 

and pharmaceutically acceptable acid addition salts thereof,
wherein X3 is selected from the group consisting of S, or 0, Rg is methyl ketone or is as defined in claim 4, R5 is saccharide as defined in claim 4, and X4, R
j
, R
2
, R3, R7, Rg, R9, RJQ, RJJ and Rj
2
 are defined as in claim 4, which comprises the steps of
1) coupling an isochroman
wherein R5 is H and Rg, R7 and Rg are defined as above with a saccharide of formula,
20
wherein R9, RJQ, RJJ and R
j2
 are defined as above to yield a bicycbc saccharide of formula,
21
269
SUBSTITUTE SHEET 


 2) oxidatively demethylating die medioxy groups of foπnula (21) to yield a bicycbc quinone saccharide of formula,
12
3) cycle-adding said bicyclic quinone saccharide a diene of formria,
wherein L is a bving group selected from the groiφ consisting of halogen, tosyl, benzoyl, p-nitrobenzoyl and -OR or -SR, wherein R is selected from the group consisting of hydrogen C
j
.
j
g alkyl, C
j
.
j
g acyl, C
j
.
j
g aryl, C 
j
. 
j
g alkylsilane and dimethylamino, to yield a compound of formria
43. A process, according to claim 39, for the preparation of a compound of formula,
270
SUBSTiTUT r* incc I 

and phaimaceuticaUy acceptable acid addition salts thereof, .
wherein X3 is selected from the group ccmsisting of NR, S, or 0, Rg is methyl ketone or is as defined in claim 4, R5 is saccharide as defined in claim 4, and Rj, R , R3, R7, Rg, R9, RJQ, R 
j j
, R
j2
, and X4 are defined as in claim 4; which comprises the steps of
1) coupling the quinone of formria,
wherein R5 is OH with a saccharide of formula,
"•"fisfi. . ^f _*,r*1
S
 «,
R
1 2
1 R
1 0
18a 18b
wherein L is a leaving groiφ selected firom the groiφ consisting of halogen, tosyl, benzoyl, p-nitrobenzoyl and -OR or -SR, wherein R is selected from the groiφ consisting of hydrogen C
j
.
j
g alkyl, C
j
.
j
g acyl, C
j
.
j
g aryl, C
j
.
j
g alkylsilane and dimethylamino, to yield a bicycbc quinone saccharide of the formula,
271
SUBSTITUTE SHEET 

2) and cycbcally coupling said quincme saccharide with the diene of formria, wherein L is defined as above
16
to yield a tricycbc saccharide of formula,
44. A process according to claim 39, for the preparation of a compound of formula,
and pharmaceutically acceptable acid addition salts thereof,
wherein X3 is selected from the groiφ consisting of N, O, or S, X 
j
 and X
2
 are 0, R5 is hydroxyl and R
j
, R , R3, Rg, R7, Rg, and X4 are defined as in claim 4, which comprises the steps of
272
SUBSTITUTE SHEET 


 1) selecting a precurser benzoate compound of formula,
and condensing it witii a dihalomethyl dimethoxybenzene,
wherein said halogens are independently selected firom the groiφ consisting of Cl, Br and I and X3 is selected firom the groiφ ccmsisting of O, S, and N to yield a dimethoxyisochroman of formula,
14
2) oxidatively demethylating die methoxy groups to yield a bicycbc dioxoisothiochroman; die resulting dioxoisothiochroman is cycbcally coupled with the diene of formula,
wherein A is NR and R is selected from de groiφ consisting of H, C
j
.
j
g alkyl, and C .J6 aryl, and L is a bving group selected from die group ccmsisting of halogen, tosyl,
273
SUBSTITUTE SHEET 


 benzoyl, p-nitrobenzoyl and -OR or -SR, wherein R is selected from the groiφ consisting of hydrogen C
j
.
j
g alkyl, C
j
.
j
g acyl, C
j
.
j
g aryl, C
j
.
j
g alkylsilane and dimethylamino, to yield an anthracenedione of the formula,
the resultant compound may optionally be converted to die hydroxyl-foπn yielding a coπφound of formula,
the resritant compound may be optionally coupled with a saccharide of formula,
20
wherein Rg, RJQ, RJJ and. R
j2
 are defined as in chum 4, to yield a tricycbc saccharide of formria,
45. A process according to claim 39, for the preparation of a ccmφound of formula,
274
SUBSTITUTE SHEET 

and pharmaceutically acceptable acid addition salts thereof,
wherein Rj, R
2
, R3, R7, Rg, R9, RJQ. RJJ. RJ2» *
nα
' X4 «** defined as in claim 4; which comprises the steps of
1) selecting a dimethoxythioisochroman of formula,
and coupling it with a saccharide of formria,
20
2) to yield a dimethoxybicycbc saccharide of formula,
3) oxidatively demethylating the methoxy groups to yield a dioxobicycbc thioisochroman or formria,
275
SUBSTITUTE SHEET 

4) cycloadding said dioxobicycbc isochroman with a diene of formula,
to yield a thiotncycbc saccharide of formula,
46. A process according to claim 39 which comprises a further preliminary step of 1) selecting a precurser compound of formula
wherein Rg, and R7 are electron withdrawing groups as defined in claim 4, X3 is O or S, and Pg is a protecting groiφ selected from the group consisting of acyl, trifluoracyl, benzoyl,
P-nitrobenzyl,
276
SUBSTITUTE SHEET 


 C
j
.
j
g alkylsilane, C
j
.
j
g aiyl, Cj.jg acyl, 
c
l-16 * . and condensing said precursor compound with a dihalomethyl dimethoxybenzene of formria
wherein X
j j
 and X
j2
 are independently selected from the group consisting of Cl, Br, and I, to yield a dimethoxy bicycbc precursor chemical of formula
14
47. A process according to claim 39 which comprises a further step of attaching a protecting group to at least one of the moieties at positions R
j
, R
2
, R3, Rg, R7 and Rg and positions R9, RJQ. RJJ, and Rj
2
 of the saccharide prior to glycosylation and then removing said protecting group or groiφs.
48. A process according to claim 47 wherein said protected positions are at R
j
, R
2
 and R3;
49. A process according to claim 39 wherein X3 is O or S;
50. A process according to claim 41 wherein X3 is O or S;
51. A process according to claim 42 wherein X3 is O or S;
52. A process according to claim 43 wherein X3 is O or S;
53. A process according to claim 44 wherein X3 is O or S;
54. A process according to claim 39 wherein X3 is O;
277
SUBSTITUTE SHEET 


 55. A process according to claim 41 wherein X3 is O;
56. A process according to claim 42 wherein X3 is O;
57. A process according to claim 43 wherein X3 is O;
58. A process according to claim 44 wherein X3 is O;
59. A process according to claim 45 wherein X3 is O;
60. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least one conφound according to claim 1 and a pharmaceutical acceptable carrier.
61. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least cme compound according to claim 3 and a pharmaceutical acceptable carrier.
62. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least cme compound according to claim 4 and a pharmaceutical acceptable carrier.
63. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least one compound according to claim 5 and a pharmaceutical acceptable carrier.
64. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least cme compound according to claim 6 and a pharmaceutical acceptable carrier.
65. A pharmaceutical composition possessing antitumor activity, comprising an effective amount of at least one coπφound according to claim 7 and a pharmaceutical acceptable carrier.
66. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least one compound according to claim 8 and a pharmaceutical acceptable carrier.
67. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least one conφound according to claim 13 and a pharmaceutical acceptable carrier.
68. A pharmaceutical composition possessing anti-tumor activity, comprising an effective amount of at least one conφound according to claim 14 and a pharmaceutical acceptable carrier.
69. A pharmaceutical composition according to claim 1, wherein said conφound is
278
SUBSTITUTE SHEE 


 combined with an agent facilitating targeting of said combination to tumor or cancer cells.
70. A pharmaceutical composition according to claim 3, wherein said compound is combined with an agent facilitating targetting of said combination to tumor or cancer ceUs.
71. A compound according to claim 1 selected from die group consisting of:
(l'-S, l'S, 3-R)-medιyl-(l-[2',3',4',6' tetradeoxy-3'-medκ
>
xy-4'-0-ιnethanesulfonyl-L- lyxohexopyιanoβe)-5, 10-dioxo-3,4,5, 10 tetrahydronaphtho-[2,3-c] pyπn-3-yl) ketone
BCH-2072 l-Methoxy-5, 10-dioxo-5, 10-dihydro-lH^ιaphdιo[2,3-c]pyran-3-[N-(3-dimedιylamino- propyl)caιboxamide]
 (BCH-2167) l-Methoxy-5, 10-dioxo-5, 10-dihydro-lH^ι_φhtho[2,3-c]pyran-3-[N-(3-dimethylamino- propyl)carboxamide]
 hydrochloride monohydrate (BCH-2051)
(lS,2'S,3S,5'S)-MethyHl-CH^-BOC-Serme-Leucine-Me e8ter]
-5,10-dioxo-3,4,5,10-tetrΔ naphtho [2,3-c] pyran-3-yl) ketone (BCH-1998) (lS,2'S,3S,5'S)-Medιyl-(l-0-[Sαine-Leucine-Me ester]
-5, 10-dioxo-3,4,5, 10-tetrahydro-l-H-naphtiιo
[2,3-c] pyran-3-yl) ketone hydrochloride (BCH-2000) (IS, 2'S, 3R) and (IR, 2'S, 3S)-methyl-(l-[0-serine methyl ester]
-5, 10-dioxo-3,4,5, 10- tetrahydronaphtaleno [2,3-C] pyran-3-yl) ketone hydrochloride. (BCH-1654) (IS, 2'S, 3R) and (IR, 2'S, 3S)-m_ΛyHHO-N-BC -ι 
>
linol]-5,l()-dioxo-3,4,5,10-tetr__hydπ
>
-l-H- naphtiio [2,3-C] pyran-3-yl) ketone BCH-2067 (IS, 2'S, 3R) and (IR, 2'S, 3SVm_ΛyKHCH»rolinol]
-3,4,5,12-tetrahydronaphto-[2,3-C] pyran-3-yl) ketone hydrochloride salt (BCH-1658)
(l'-S, 1-R, 3-S) and (l'-S, 1-S, S-R^-cyaiω-l-P'.S'.β'-trideoxy-S'-trifluoioacetaimdo^'^iydroxy-L- lyxohexopyranose)-5,10-dioxo-3,4,5,10-tetrahydronaphtho-[2,3-C!] pyran-3-yl (BCH-
1688) (l'-S, 1-S, 3-R) and (l'-S, 1-R, 3-S meU.yl-{l-[2' , ,4' ,6' tetnd∞xy-3'-trifluoroacet_unido-4'-0- ιnethane-srifonyl-L-lyxohexopyranose)-5,10-ώoxo-3,4,5,10 tetrahydπmaphdιo-[2,3-c] ' pyπm-3-yl) ketone BCH-2095 (l'-S, 1-S, 3-Rym~t--yl-(l-[2',3',4',6' tetradeoxy-3'-trifluoroa∞taιmάo^'-C 2-brιmκ
>
-acetyl)-L- lyxopyranoβe]-5, 10-dioxo-3,4,5,10 tetrahydronaphtho-[2,3-c]
 pyτan-3-yl) ketone BCH-
2105 (l'-S, 1-R, 3-S)-methyl-(l-[2',3',4*,6' tetradeoxy-3'-methoxy^4'-0-methanesulfbnyl-L- lyxohexopyranose)-5,10-dioxo-3,4,5,10 tetrahydronaphtho-[2,3-c] pyran-3-yl) ketone
BCH-2070 (1-S, 3-R) and (1-R, 3-S)-methyl-(l-(l-ιnethoxy-4-oxocyclohexyloxy)-5,10-dioxo-
3,4,5,10 tetrahydronaphto-[2,3-c] pyran-3-yl) ketone BCH-20%
279
SUBSTITUTE SHEET 


 (IR, 3S)-l-(2',3',6'-trideoxy-3'-trifluc ιacfrfamido-4'-hydroxy-l,5-dihydι^
5, lO-dioxo-3,4,5, 10-tetrahydτo-lH-naphdιo-[2,3-c] pyran BCH-2144 (IS, 3R)-l-(2',3',6'-trideoxy-3'-trifluoroaceta__rido-4'-hydιoxy-l,5-^
5,10-dioxo-3,4,5,10-tetrahydro-lH-naphtho-[2,3-c] pyran BCH-2145 (l'S, IR, 3S)-5,10-dioxo-3-πιedκϊxyπιedιyl-l-(2\3\6'-trideoxy-3
,
-trifluoroacetamick
>
-L- lyxohexopyranose)-3,4,5, 10-tetrahydro-lH-naphdιo-[2,3-c]-pyran (BCH-1691) (l'S, IS, 3R)-5,10-dioxo-3-metboxymedιyl-l-(2',3',6'-trideoxy-3'-ti fiuoroacetamiάo-L- lyxohexopyranoβe)-3,4,5, 10-tetrahydro-lH-naphdιo [2,3-c]
 pyran (BCH-1693) (l'S, IR, 3R)-5,10-άιoxo-3-eUιyl-K2',3',6'-trideoxy-3'-trifiuoιoaceta__ri^ 3,4,5,104etnhydro-lH-naphtho-[2,3-c] pyran (BCH-2026)
(l'S, IS, 3S 5,10-dioxo-3-edιyl-l-(2',3',6'-trideoxy-3'-trifluoroacetamido-L-lyxohexopyranose^
3,4,5, 10-tetrahydro-lH-naphtho-[2,3-c]-pyran (BCH-2020) (l'S, IS, 3S 5,10-dioxo-3-edιyl-l-(2',3',6'-trideoxy-3'-ammo-L-lyxohexcφyr_uιoβe)-3,4,5,10- tetrahydro-lH-naphUιo-[2,3-c]
-pyran (BCH-2021) Trans-5,10-dioxo-l-*ceta__rido-3-etiιyl-3,4,5,10-tetrahyd^ (BCH-2027)
3-ethyl-5,10-dioxo-3,4,5,10-tetrahydro-lH-naphto-[2,3- ] pyran (BCH-2154) (l'S, IR, 3S)-5,10-d^oxo-3-iso| φyl-l-(2\3\6'-trideoxy-3'-trifluoroarrtsmido-L-lyxohexopyranose)-
3,4,5, 10-tetrahydro-lH-naphtho-[2,3-c]-pyιan (BCH-2053) (l'S, IS, 3R)-5,10-dioxo-3-iβoρπφyl-l-(2\3\6'-trideoxy-3'-trifluoτoaceta^ 3,4,5, 10-tetrahydro-lH-ιuφhtho-[2,3-c]
-pyran (BCH-2052)
(trans)-5, 10-dioxo-3-iscφropenyl-l-medιoxy-3,4,5, 10-tetrahydro-lH-naphUιo-[2,3-c]-pyran (BCH-2148) (l'S, IR, 3S 5,10-dioxo-3-iatφropenyl-l-(2',3',6'-trideoxy-3'-triflιιoιo
3,4,5, 10-tetrahydro-lH-naphto-[2,3-c]-pyran (BCH-2153) (l'S, IS, 3R 5,10-dioxo-3-i80p^openyl-l-(2 3 6
,
 -trideoxy-3 '-trifluoroacetamido-L-lyxohexopyranore)^ 3,4,5, 10-tetπAydro-lH-αaphtcH2,3-c]-pynn (BCH-2152)
(l'S, IR, 3S)-5,10-dioxo-3-medιoxyca__bonyl-l-(2',3',6',trideoxy-3'-trifiuoroacetamido-L- lyxcmexopyranose)-3,4,5,10-tetrahydro-lH-naphdιo-[2,3-c]-pyrano (BCH-2128) (l'S, IR, 3S)-isopπφyl-[l-(2',3',6'-trideoxy-3'-trifiuoroacetamidc
>
-L-lyxc
>
hexcφyranoκ 3,4,5, 10-tetπώydro-lH-n_φhtho-{2,3-c]-pyranyl]
-ketone (BCH-2112) (l'S, IR, 3S)-5,10-dioxc
>
-3-i_xφropoxyαubonyl-H2',3',6'-trideoxy^ lyxohexopyranose)-3,4,5,ip-tetrahydro-lH^ιaphtho-[2,3-c]-pyran (BCH-2122) (l'S, IS, 3R)-5,10-dioxo-3-iι»propoxycartκmyl-l-(2\3\6'-trideoxy-3
,
-trifluoroacetamido-L- lyxohexopyranose)-3,4,5, 10-tetrahydro-lH-naphtho-[2,3-c]-pyran (BCH-2121) (1 'S, lS)-5, 10-dioxo-3,3-dimethoxymethyl-l-(2' ,3 ' ,6 '-trideoxy-3 '-triflιιoroacetamido-4'-0-p- ritrobenzoyl-L-lyxohexo-pyranose)-i80chroman (BCH-1697)
(l'S, IR, 4R)-5,10-dioxo-4-ethyl-l-(2',3',6'-trideoxy-3'-trifluoroacetaιmdo-L-lyxohexopyrano_^
3,4,5, 10-tetrahydro-lH-naphtiιo-[2,3-c] pyran (BCH-2091) (l'S, IR, 3S)-5,10-dioxc
>
-3-phenyloxymediyl-l-{2\3\6'-trid^xy-3
,
-trifluoroacetamido-L- lyxohexcφyranose)-3,4,5,10-tetrahydro-lH-naphtho-[2,3-c] pyran (BCH-2032)
280
SUBS ϊi i
'
ϋTE SHEET 


 (1'S,1S,3S) and (l'S,l-R,3-R)-3- 2',3',6'-trideoxy-3'-trifluoroaMtaιrido-4' ιydroxy-L- lyhohexopyraiK)ee]-5,10-dioxo-3,4,5J0-tetrahydionaphto-[2,3-c]
-pyran-3-yl)-propene
(BCH-2031) (1 'S,l-R,3-R)-3-([2',3 ' ,6'-trideoxy-3 '-trifluoroacetanndo-4'-hydroxy-L-lyhohexopyranoee]-5, 10-dioxo- 3,4,5, 10-tetrahydronaphto-[2,3-c]
-pyran-3-yl)-propene (BCH-2163)
(1 '-S, l-R,3-S)-3-([2' ,3' ,6'-trideoxy-3 '-trifluoroacetaπήdo-4'-hydroxy-Wyhohexcφyιanoβe]-5, 10-dioxo-
3,4,5, 10-tetrahydronajΛdκ
>
-[2,3-c}-pyran-3-yl)-propene (BCH-1649) (1'S,1S,3R) and (l'-S,l-R,3-S)-3-([2',3',6'-trideoxy-3'-triflucrroacetaimdo^
,
-hydroxy-L- lyhohexopyraικ_βe]-5,10-dioxo-3,4,5,10-tetrahydronaphtho-[2,3-c]
-pyran-3-yl)-propene (BCH-1648)
(l'-S, 1-R,3-S,4a-S, 10a-S)-methyl-(l-[2' ,3' ,4',6'-t^^ lyxohexopyranose)-4a, 10a-epoxy-5, 10-dioxo-3,4,5, 10-tetrahydronaphtho-[2,3-c] pyran-
3-yl) ketone (BCH-2141) (l'-S, 1-S,3-R,4a-R, 10β-R)-methyl-(l-[2' ,3 ',4',6'-tetradeoxy-3 '-ιιιethoxy-4'-0-ιιιethanesrifonyl-L- lyxohexopyranoβe)-4a, lOa-epoxy-5, lO-dioxo-3 ,4,5, 10-tetrahydronaphtho-[2,3-c] pyran-
3-yl) ketone (BCH-2149) (1S,3R,1'S,5'S,6'S) and (lR,3S,l'S,5'S,6'S)-ιnethyl-(H4'trifiuoroacetamidc
>
-5'- methyltetrahydropyranyl]-5, 10-dioxo-3,4,5, 10-tetrahydranaphthaleno-[2,3-c]
 pyran-3- yl) ketone (BCH-1673) (1'S,1S,3R 3 (oximoethyl)-5, 10-dioxo- 1 (2,3,6-trideoxy-3-trifluoroacetanudo-L-lyxohexopyτanoβe)-
3,4,5,10-tetrahydro-lH-αaphtho-[2,3- ] pyran BCH-2101 (l'S, lR,3S)-3(oximoethyl)-5, 10-dioxo- 1 (2,3,6-trideoxy-3-trifluoroacetaιmdo-L-lyxohexopyranoβe)-
3,4,5, 10-tetrahydro-lH-naphdιo-[2,3-c]-pyτan BCH-2115 (1 's, lS,3R)-3-(trifluoroacetamidoetiιyiχ-5,10-dioxo-l-(2',3 ', '-trideoxy-3 ' ,4'-dihydroxy-L- lyxcmexopyranoβe)=-3,4,5,10-tetrahydro-lH-naphdιo-[2,3-c]
^)yran (BCH-2018)
(1 'R, lR,3S)-3-aceto-5, 10-dtoxo-l-(2-deoxy-2-cUoroethyl-ritro8θureido-D-gluccφyrano8e)-3,4,5, 10- tetrahyd__o-lH-naphtiιo-[2,3-c]pyran (BCH-2038) 3-Aceto-5, 10-dioxo-l-methoxy-5, 19-dihydro-lH-naphUκ
>
-[2,3-c]-pyran (BCH-2129) (1R,3S) and (lS,3R)-3-aceto-5, 10-dioxo- 1 (4-chloroeUιylnitιosoureido cyclohexy -oxy)- 3,4,5, 10tetrahydro-lH-naphtho-[2,3-c]
-pyran (BCH-2114) l-meωoxy-3-N-anilriylca_rbonyl-5, 10-dioxo-5, 10-dihydro-lH-naphtiιo-[2,3- ]-pyran (BCH-2044) l-methoxy-3-(3-N-pyrrobdinomylpropybuninocarbonyl)-5, lO-dioxo-5, 10-dihydro-lH-naphtho-[2,3-c]
- yran (BCH-2166) (3-N-hydrochloroimidazolylpropyl)-l-methoxy-5, 10-dioxo-5, 10-dihydro-lH-oaphtho-[2,3-c]-pyran-3- carboxamide (BCH-2157)
3-edιyldύocarbonyl-5,8-ώoxo-l,3,4,5,10-pentahydro-naphdιo-[2,3-c]-pyran (BCH-2003)
3-(5'-tosyloxazolyl)-5, 10-dioxo-l,3,4,5, 10-pentahydro-naphtho-[2,3-c]
-pyran (BCH-2155)
(1 'S, lS,3R)-l-(3'-trifluoroacetamido-2' ,3 ' ,6'-trideoxy-lyxo-L-hexopyranose)-3-ιnethoxycarbonyl-3- methyl-3,4,5, 10-tetrahydro-5, 10-dioxo-n_φhdιo-[2,3-c]-pyran (BCH-2076)
281
SUBSTfTUT * 
<
■ ~
 ~~- ~~- T 


 Mediyl (l^nethoxy-5,10-dioxo-3,4,5,10-tetπdιydro-lH-M_phdιo[2,3-c]pyran-3-yl) formate (BCH-2043) l-Methoxy-5,10-dioxo-5,10-dihydro-lH-naphtho[2,3- ]
pyr__n-3-carboxybc acid (BCH-2161)
(1 ,3-trans)-l-methoxy-3-caιboxyl-5, 10-dioxo-3,4,5, 10-tetrahydro-lH-narAdιo-[2,3-c]-pyran (BCH-2045)
(l,3-ds)-l-medιoxy-3-c_aιτκ)xyl-5,10-dioxo-3,4,5,10-tetrahydro-lH-naιΛthc
>
-[2,3-c]-^ (l,3-traωH-metl»xy-3-N-an__foylcarb^
(BCH-2041) (1 ,3-cis
>
l-methoxy-3-N-anilinylcarbonyl-5, lO-dioxo-3,4,5, 10-tetrahydro-lH-n_φhtho-[2,3-c]-pyran
(BCH-2042) (l'S, lR.SS.H∑'.S ' ,6'-trideoxy-3 '-triflικ
>
τoa_»tamido-L-lyxohexopyτanose-3-[5'-to8yloxazolyl]-5, 10- dioxo-3,4,5,l(Metrahyd^lH-naphthcH2,3-c]
-pyran (BCH-2150)
(rS,lS,3R 2',3\6
,
-triΛ»xy-3'-trifluoroβ_»tamido-L-lyxohexopyranoβe-.^ dioxo-3,4,5,10-tetnhydro-lH-naphtiιo-[2,3-c]-pyran (BCH-2151) (l,3-tr_ms l-medιoxy-3K3'-aminothiazolyl)-5,10-dioxo-3,4,5,10-tetrahydro-lH-naph
(BCH-1616) (l,3-transH-ιnedrøxy-3-dimethoxypho
β
ρhono pyran (BCH-1674) (l'S,lR,3SH-(3
,
-triflιιoroa__»ta__rido-2',3',6'-trideoxy-M^ lH-naphdιo-[2,3-c]-pyran (BCH-2077)
(l'S,lS,3R)-l-(3'-trifluoroa∞t_umdo-2',3',6'-trideoxy-lyxo-L^ιexcφyrancweH 3,4,5, 10-tetrahydro-5,10-dioxo-naphthc
>
-[2,3-c]-pyran (BCH-2082)
(1 'S, lS,3R)-l-(3'-trifluoroacetamido-2' ,3 ' ,6'-trideoxy-lyxo-L-hexopyranose)-3- dimethoxyphosphonoacetyl-3,4,5, lO-tetrahydro-5, 10-dioxo-naphtho-[2,3-c]-pyran
(BCH-1690) (rS,lS,3SH-(3
,
-trifluoroacetanήdo-2
'
,3 6'-mdeoxy-lyxo-L^^ memyl-3,4,5,10-tetrahydιo-5,10-dioxό-najAdιo-[2,3-c]-pyran (BCH-2081)
(l'S,lS,3S)-l-(3
,
-trifluoroacetamido-2',3\6
,
-trideoxy-lyxo-L-bexopyranoβe)-3- dimethoxyphosphonoacetyl-3,4,5, lO-tetrahydro-5, 10-dioxo-___aphtho-[2,3-c]-thiopyran
(BCH-2037.001) (l'S,lR,3R)-l-(3'-trifluoroa∞taπudo-2',3',6'-trideoxy-lyxo-L-hexopyιanose)-3r dimethoxyphosphonoacetyl-3 ,4,5, lO-tetrahydro-5, 10-dioxo-naphtho-[2,3-c]-pyran
(BCH-2127) (l'S,lS,3S)-l-(3'-trifiuoro«_etaιmdo-2',3',6'-trideoxy-lyxo-L-hexopyranoβe)-3-ac^ tetrahydro-5,10-dioxo-lH-naphtiιc 2,3-c]-pyran (BCH-2090) (l'S, lR,3S)-l-(3 '-trifluoroacetamido-2' ,3 ' ,6'-trideoxy-lyxc-L^excφyranose)3-diιnethylpho_φhonoacetyl- 3,4,5, 10-tetrahydro-5,10-dioxo-naphtiκ
>
-[2,3-c]-pyran (BCH-1689)
(1 'S, 1R,3S)- methyl-(l-[2' ,6'-dideoxy-3' ,4'-dihydroxy-2'-iodo-L-lyxohexopyranose]-5, 10-dioxo-
3,4,5, 10-tetrahydronaphtho [2,3-c]-pyran-3-yl) ketone (BCH-2015) (1 
*
S, lR,3S)-methyl-(l-[2' ,6'-dideoxy-3'-4'-diacetoxy-2'-iodo-L-lyxohexopyranose]-5, 10-dioxo-
3,4,5,10-tetrahydronaphdιo [2,3-c]-pyran-3-yl) ketone (BCH-1666)
282
SUBSTITUTE SHEET 


 (l'S,lS,3R)-metiιyl-(l-[2',6'-dideoxy-3',4'-dia_^^
3,4,5, 10-tetrahydronaphdιo [2,3-c]-pyran-3-yl) ketone (BCH-1667) (l'S,lS,3R)-medιyl-(l-[2',6'-dideoxy-3',4'-dihydroxy-2'-ic_do-L-lyxc^xcφyranose]
-5,10-dioxo- 3,4,5, 10-tetrahydronaphύιo [2,3-c]-pyran-3-yl)-ketone (BCH-2014) (1 'S,lR,3S)-methyl-(l-[2',6'-dideoxy-3',4'-diacetoxy-2'-bro
3,4,5, 10-tetrahydronaphtiκ
>
-[2,3-c]-pyτan-3-yl) ketone (BCH-2100) (1 'S, lS,3R)-medιyl-(l-[2' ,6'-dideoxy-3' ,4'-diacetoxy-2'-bromo-L-lyxohexopyranoβe]
-5, 10-dioxo-
3,4,5,10-tetrahydronaphtho-[2,3-c]-pyran-3-yl) ketone (BCH-2099) (l'S, lR,3S)-methyl-(l-[2' ,3' ,6'-trideoxy-2'-iodo-3'-trifiuoroacetamido-4'*ydroxy-L- lyxc^xcφyranoβe]
-5,10-dioxo-3,4,5,10-tetrahydronaρhthc
>
-{2,3-c]-pyran-3-yl) ketone
(BCH-2023) (l'S,lS,3R)-medιyl-(l-[2',3',6'-trideoxy-2'-iodo-3'-trifluoιoac«taιridc-4'-hydroxy-L- lyxohexopyranose]-5, lO-dioxo-3 ,4,5, 10-tetrahydronaphtho-[2,3-c]
-pyran-3-yl) ketone (BCH-2022) (l'S, IR, IS) and (1 'S, lS,3R)-metiιyl-(l-[2' ,6'-dideoxy-3 ' ,4'-diacetoxy-2'4odo-L-arabino-hexopyranc
>
se]- 5,10-dioxo-3,4,5,10-tetrahydronaphtiιo-[2,3-c]
-pyran-3-yl) ketone (BCH-2065) (l'S, 1S,3R) and (1 'S, lR,3S)-methyl-(Hdideoxy-2' ,6'-dihydroxy-3' ,4'-L-lyxohexopyranose]-5, 10- dioxo-3,4,5,10-tetr_dιydronaphUιo-[2,3-c]
-pyran-3-yl) ketone (BCH-2117) (l'S,lS,3R) and (rS,lR,3S)-meΛyl-(l-[dic_-»xy-^ 3,4,5,10-tetrahydronaphdιo-[2,3-c]-pyran-3-yl) ketone (BCH-2118)
(l'S,lS,3R)-methyl-(6 and 9^ydroxy-H2',3',6'-trideoxy-3'-trifiuoroacetaιmdo-4'-hydroxy-L- lyxohexopyιano_M]-5,10-dioxo-3,4,5,10-tetrahydroruφhtho-[2,3-c]
-ρyran-3-yl-ketone (BCH-2078) Metiιyl-(l-O-[2
'
-piperidinemethaιωl]-5,10-dioxo-3,^ ketone, racemic, hydrochloride (BCH-2069)
(1R,3S,1'S) and (lS,3R,l'S)-Me
&
yKl-[2',3',4',6'-tetπκleoxy-3',4'-bi8-trifl^^ arabinohexopyranoβe]-5,10-dioxo-3,4,5,10-tetrahydron_φhthrieno-[2,3-c]
 pyran-3-yl) ketone (BCH-2104 and BCH-2102) (1R,3S,1'S) and (lS,3R,l'S)-Methyl-(l-[2',3',4',6'-tetradeoxy-3',4'-bi8-trifluoroaι»taιmdo-^ arabinohexopyranose]-5,10-dloxo-3,4,5,10-tetrahydronaphthaleno-[2,3-c]
 pyran-3-yl) ketone (BCH-2047) Mediyl-(l-O-[N-BOC-3-piperidinemedianol]-5,6-dioxc
>
-3,4,5,10-tetraty yl) ketone, mixture of isomers (BCH-2060) Methyl-(l-O-[3-piperidinemeU_anol]-5,10-dioxo-3,4,5,10-tetraty ketone hydrochloride salt, mixture of isomers (BCH-2061)
(lR,3S,l'S) and (lS,3R,l'S)-Methyl-(l-[2',3
,
,4',6'-tetndeoxy-3',4'-bi8-trifluoroa∞taιm arabinohexopyranose]-5, 10-dioxo-3,4,5, 10-tetrahydronaphthaleno-[2,3-c]
 pyran-3-yl) ketone (BCH-2104) (lS,3R,l'S)-MeUιyl-(l-[2',3',4',6'-tetradeoxy-3',4'-bis-trifiuoroacetaιmdo-I^ara^
283
SUB
CΥ
 « --
<
.-
*
<
«_. k i \ i » ϊ * -"* 
~
 * t-
~
 !
•»«■
__■ 


 5,10-draxo-3,4,5,10-tetnhydronaphtiιaleno-[2,3- .] pyran-3-yl) ketone (BCH-2102)
72. A coπφound according to Claim 1 selected from the group consisting of:
(l'S, IR, 3S)-5,l()-dioxo-3-metfaoxycaιbonyl-l-(2',3 6
,
-trid∞xy-3'^ ritrobenzoyl-L-lyxohexcφyrano_»)-3,4,5,10-tetrahydro-lH^ιaιΛUκ)-[2,3-c]-pyτan. Methyl (l,5,8-trimethoxy-iβochroman-3-yl) formate Methyl (l-Methoxy-5,8-dioxo-5,8-dihydro-isochroman-3-yl) formate
(1S,2'S,3R,5'S) and (lR,2'S,3S,5'S)-HC-N-BOC-Seriιι^Leιιcine-Me eβter]-3-βceto-5,8-dimethoxy- isochroman (IS, 2'S, 3R) and (IR, 2'S, 3S)-l-[0-serine methyl ester]
-3-aceto-5,8-dimethoxy isochroman. (IS, 2'S, 3R) and (IR, 2'S, 3S)-HO-N-BOC-prolinol]-3-acetyl-5,8-dimethoxy isochroman l-hydroxy-3-cyano-5, 8-dimethoxy isochroman l-hydroxy-3-cyano-5,8-dioxo-5,8-dihydroisochrornan
(l'S, IS, 3R) and (l'S, IR, 3S)-5,10-dioxo-3^yaιK-l- 3\6\-tric_TOxy-3
,
-triflιK)roacetamid ritrobe__ιzoyl-L-lyxohexopyranoM)-3,4,5,10-tetπώydro-l^ 5,8-Diπκdκ)xy-3-(propane-2-cmeH-
<
2\3\6'-trideoxy-3'-trifluor^ lyxohexopyranoβe)-isochιoman
5,8-Dioxo-3-(propane-2-one)-l-(2',3',6'-trideoxy-3'-trifluoιoa∞tamido-4'-O -m lyxohexopyranoβeHsochroman (IR, 3S) and (1-S, 3RH-(2\3\6
'
-trideoxy-3'-trifluoroaα_tamido-4'-0-p-rit^^ lyxohexo-pyranoβe-2-yl)-5,8-dimemoxy-3-acetoi8cxΛroman (IR, 3S)-l-
<
2\3\6'-trideoxy-3'-trifluoroa∞taπudo-4*-O -ritrobenzyloxy-l,5-dihydro-L- lyxohexopyranoβe-2-yl)-5,8-dioxoisochroman (IS, 3R)-l-(2' ,3' ,6*-trideoxy-3 '-trifluoroacetamido-4'-0-p-nitrobenzyloxy-l ,5-dihydro-L- lyxohexopyranose-2-yl)-5,8-dioxoisochroman (l'S, IR, 3S)-5,8-dioxo-3-πιethoxym_^yl-l-{2',3',6'-trideoxy-3'-tri^ ritrobenzoyl-L-lyxohexo-pyranoβe)-5,8-dihydroi_ )chroman
(l'S, IR, 3S) and (l'S, IS, 3R)-5,8-dioxo-3-methoxymethyl-l-(2\3\6'-trideoxy-3
,
-trifluoroacetamido-
4*-C«-p-mtrobeozoyl-L-lyxohexo-pyranoβe)-5,8-dihydroi8ochrornan (l'S, IR, 3R)-5,8-dimetiκ
>
xy-3-ethyl-l-(2\3\6'-trideoxy-3'-trifluoτo lyxohexopyranoseHsochroman (l'S, IR, 3R)-5,8-dioxo-3-e%l-K2',3',6'-trideoxy-3'-4rifluoroaceta__riά^ lyxohexopyranose)-isochroman (l'S, IS, 3S)-5,8-dioxo-3-etiiyl-l-(2\3 6
,
-trideoxy-3
,
-trifluoroacetaimdo-4'-0-p-mti benzoyl-L- lyxohexo-pyranose)-5,8-dihydro-isochroman (trιms)-l-acetamido-5,8-dioxo-3-emyl-5,8-dihydro-isoclιroman
284
SUBSTITUTE SHEET 


 (l'S, IR, 3S) and (l'S, IS, 3R)-5,8-dtoxo-3-iaopropyl-l-(2',3',6'-trideoxy-3'-triflι__orc_acetanύdc^ mtrobenzoyl-L-lyxolιexopyraιιcιβe)-5,8-dihydro-isochιoman (40:60) (l'S, IS, 3R)-5,8-dioxo-3-i_xφrcφyl-l-(2',3',6'-trideoxy-3
,
-triflιrøroacetaιmdo-4'-0-p-mb^ lyxohexopyιanoβe)-5,8-dihydro-i__ochroman (40:60) (l'S, IS, 3R)-5,8-dimed»xy-3-isopropcnyl-l-(2',3',6'-trid∞^ ritrobenzoyl-L-lyxohexo-pyranoβe) isochroman. (l'S, IR, 3S)-5,8-dimedιoxy-3-i_»propeoyl-l-{2 3 6'-trideoxy-3
,
-trifluoroacetaπήdo-4
,
-0-p- nitrobenzoyl-L-lyxohexopyranose) isochroman. (l'S, IR, 3S) and (l'S, IS, 3R)-5,8 dimethoxy-3-methoxycaιbonyl-l-(2',3',6'-trideoxy-3'- triflιιoroaceta__rido-4'-0-p^t_robenzøyl-Myxohexop
(l'S, IR, 3S) and (l'S, IS, 3R)-5,8 dfoxo-3-methcκycarbonyl-l-(2',3\6'-trid∞^^
4'-C
^
p^trobenzoyl-L-lyxohexopyranoβe)-5,8-dihydro-i-_ochroman. iscφropyl-(5,8-dimethoxy-i__ochroman-3-yl)-ketone 5,8-dimethoxy-3-iβopropoxyc_arbonyl-isochroman 5,8-dimethoxy-3,3 bis (dimethoxymethylHsochroman
(l'S, lS)-5,8-dimeUtoxy-3,3-dimedtoxymeUιyl-l-(2',3',6'-trideoxy-3'-trifluoιoacetaιmdo^ ritrobenzoyl-L-lyxc)hexopyranoee)-isochroinan (l'S, lS)-5,8-dioxo-3,3-dimethoxym_Λyl-l-
<
2',3\6
,
-trideoxy-3'-trifluoroacetamido-4
,
-0^ ritrobenzoyl-L-lyxohexopyranoβe)-isochroman (l'S, IR, 4R)-5,8-dimethoxy-4-euιyl-l-(2\3 6
,
-trideoxy-3
,
-trifiuoroacetaπιido-4
,
-C-p-m lyxohexo-pyraικ»e)-i8θchroman (l'S, IS, 4S 5,8-diπ_ethoxy-4-ethyl-l-(2',3',6'-trideoxy-3'-trifluoroac^^ lyxohexo-pyranoβe)-isochroman (l'S, IR, 4R)-5,8-dioxo-4-ethyl-l-(2',3',6'-trideoxy-3'-triflittioaceta^ lyxohexopyianose)-isochroman
(l'S, IR, 3S)-5,8-di__κthoxy-3-ph∞yloxymedιyl-l-(2\3\6 mtrobenzoyl-L-lyxohexopyπ_αoβe)-i8θchroman (l'S, IR, 3S 5,8-dioxo-3-phenyloxymedιyl-l-(2',3',6'-tideoxy-3'-trifluoιoacetaιmdo-4'-Oφ- mtrobenzoyl-L-lyxohexopyranoβeH∞chrornan 5,8-dimethoxy-3-(2-propenylH8θchroman
(1'S,1S,3S) and (rS,l-R,3-RH
<
2',3',6',-trideoxy-3'-trifiuo_roaceta__ri^ lyxohexopyranose)-5,8-diιιιethoxy-3-(2-pιop∞ylH'tochroman (1 'S, l-R,3-R)-l-(2' ,3 ' ,6\-triά^xy-3'-trifluoιoa_^amido^'-0-paramtrobenzoyl-L-lyxohexopyranose)- 5,8-dimethoxy-3-(2-propenyl)-i8θchroman (lS,3R-3(oximoethyl)-l (2,3,6-trideoxy-3-trifluoroa_^amidc
>
-4-p-mtrobenzoyl-L-lyxohexopyranose)- 5,89-dimethosy-isochroman (lR,3S)-3-(oximoethyl)-l (2,3 ,6-trideoxy-3-triflιrøroacetaιmdo-4-p-ritrobenzoyl-L-lyxohexopyιanose)-
5,8-dimethoxy-isochroman 3-(Trifluoroacetamido-ethyl)-5, 8-dimethoxy isochroman
285
SUBSTITUTE SHEET 


 (lS',lS,3R)-3-(triflucφιoacetamidoedιyl)-5,8-dim-*^ lyxohexopynnose)-i8ochroman (1 *R, lR,3S)-3-aceto-5,8-dimedιoxy-l(2-deoxy-2-chloroedιylureido-3,4,6-triacetyl-D-gluc^ isochroman (1 'R, lR,3S 3-a∞to-5,8-dimedmy-l(2-deoxy-2- UoroeUιylu^ isochroman (1R,3S) and (lS,3R)-3-Aceto-l (4-crioroedιylureid_ -cyclcAexyloxy)-5,8-dimethoxy-i8θchroman 3-ethylfl ocart
>
onyl-5,8-diιnethoxy-isochroman 3-ethylthiocaιbonyl-5,8-dfoxo-l,3,4,5,8-pente-lH-benzo-[2,3-c] )yrBn 3-(5'-toβyloxazolyl)-5,8-dimethoxy iaochroman
3-(5'-toβyloxazolyl)-5,8-drøxo-l,3,4,5,8-pent_dιydrobenz»-[2,3-c]-pyran
(l'S, IS, 3RH-(2',3',6'-trideoxy-I,3'-trifiuoroacetaιmdc^ dimethoxy-3-aceto-3-methyl isochroman (l's,lS,3RH
<
4'-p- trobenzoyl-3'-triflιιoroa∞tamick)-2\3\^ caιbonyl-3-medιyl-5,8-dioxo-4,5,8-trihydro-lH-benzo-[2,3-c]-pyran
3-(5'-toβyloxazolyl)-5,8-diπιethoxy isochroman (l'S, lR,3S)-l-(4'-p^ιitrobenzoyl-2' ,3 ' ,6'-trideoxy-3 '-trifiuoroa∞tamido-L-lyxohexopynnose 3-(5 "- toβyloxazolyl)-5,8-dimethoxy isochroman (l'S,lS,3R)-l-(4'-p-mtιobeαzoyl-2',3',6
,
-trid∞xy-3
,
-trifluoιoacetaιmdc toβyloxazolyl)-5,8-diπ__ethoxy isochroman
(rS,lS,3RH 
4
'-p-ritrobenzoyl-2',3',6'-trideoxy-3'-trifiw tosyloxazolyl)-5,8-dioxo-3,4,5,8-tetnhydrobenzo-[2,3-c]-pyran (l'S,lS,3R)-l-(4'-p-ritrobenzoyl-2',3',6'-tritøxy-3'-trifluoroac^^ toβyloxazolyl)-5,8-dimethoxy isochroman (l'S,lS,3RH-(4'-p- trobenzoyl-2\3 6'-triάTOxy-3'-trifl toβytoxazolyl
>
-5,8-dk
>
xo-3,4^,8-tetπ_hydrobenzo-[2,3-c]-pyran (1 'S, lS,3S)-l-(4'-p-fiitrobenzoyl-3 '-trifluoroacetamido-2',3 ' ,6'-trideoxy-lyxohexopynnoβe)-3-ιnethoxy- cari
>
ooyl-3-methyl-5,8-dimedιoxy-isochrornan (l'S,lR,3RH-(4'-p-ritrobe___2oyl-3
,
-triflιιoroaceta_^ πιethoxy-carbcnyl-3-ιnethyl-5,8-dimethoxy-iscxάroman
(l'S,lR,3S)-l-(4'-p-ritroben2oyl-3'-trifluoιoacetaιmoo-2',3',6'-trideoxy-L-lyxolιexφ π_etboxy-carbonyl-3-methyl-5,8-din_ethoxy-isochroman (l'S,lR,3R l-(4
,
-p-ritrobenzoyl-3'-trifluoroacetamid 2 3 6'-trideoxy-L-lyxohexo^ methoxy-αuτxmyl-3-methyl-5,8-dimethoxy-isochroman (l'S,lR,3S)-l-(4'-pφtrobenzoyl-3'-trifiuoroacetamido-2',3',6'-trideoxy-lyxohexopyπ.^^ carbonyl-3-methyl-5,8-dioxo-4,5,8-trihydro-lH-benzo-[2,3-c]-pyran (l'S, lS,3S)-l-(4'-p-nitrobenzoyl-3 '-trifluoroacetamido-2',3 ' ,6'-trideoxy-lyxohexopyτanoβe)-3-methoxy- carbcmyl-3-ιnethyl-5,8-dioxo-4,5,8-trihydro-lH-benzo-[2,3-c]
-pyran (1'S,1S,3S) and (l'S,lR,3R)-l-(4'-p^trobenzoyl-3'-trifiιιoιoacetamido-2',3',6'-trideoxy-L-
286
SUBSϊl ϊ Uϊc SHEET 


 lyxcAexopyranoae
>
-3-a_x
<
yl-5,8-diri hoxy-thioi-iochroman (1 'S, 1S,3S) and (1 'S, lR,3R)-l-(4'-p-nitrobenzoyl-3 '-trifluoroacetamido-2' ,3 ' ,6'-trideoxy-L- lyxohexopyrano__e)-3-acetyl-5,8-dioxo-4,5,8-trihydro-lH-benzo-[2,3-c]^yran (1'S,1S,3S) and (l'S,lS,3R)-H4'-p-mtrobenzoyl-3
,
-trifiuoroacetamido-2',3',6
,
-tridi^^ lyxohexopyraιιoβe)-3-a_»tyl-3-ιnethyl-5,8-dimethoxy-isoch_roιnan
(l'S,lS,3R)-l-(4
,
-iMUtιobenzoyl-3
,
-nifluoroa_»tamidc-2',3',6'-trideoxy-__^ly^
3-methyl-5,8-dimethoxy-isochrornan (1'S,1S,3S) and (l'S,lS,3R)-l-(4
,
 ^trobenzoyl-3'-trifliionMK«taimdo-2',3',6'-tri lyxohexopy_ranoβe 3-acetyl-3-πethyl-5,8-dioxo-4,^^ (l'S,lS,3R)[l'S,lR,3S]-5,.^dimethoxy l(2',3',6'-trideoxy-3'-triflucm)«*»taιmdo^'^
>
^trobenzoyl-L- lyxohexopyranoβe)-3-di___κthylphoβphoιιoacetyl isochroman (l'S,lS,3R)[l'S,lR,3S]-l-(2',3',6'-trideoxy-3'-tiifluoro-acetaιmdo-4'-p^trote lyxohexcφyranose)-3-dimethylphθ-φhonoacetyl-3,4,5,^ pyran (1'S,1S,3R) - 2,5-Dimethoxy-H2',6'^deoxy-3',4'-diacetoxy-2'-iodo-L-lyxohexc^ acetoisochroman (1 'S, lR,3S)-5,8-Dimethoxy-3-aceto-l-(2' ,6'-dideoxy-2'4odo-L-lyxohexopynnoee)-isochroman (l'S,lR,3S)-3-aceto-l-(2 6'-dideoxy-2'-iodo-L-lyxohexcφyιanoβe)-5,8^oxo-5,8-dihydroisoc (l'S,lR,3S)- 5,8-Dioxo-3-β__*to-l-(2\6'-diάTOxy-3 4'-dia∞^ dihydroisochroman
(l'S,lS,3R)-5,8- ioxo-3-a∞to-l-(2',6'-dideoxy-3
,
,4'-diacetoxy-2'-iodo-___^lyxohexo^ dihydroisochroman (l'S, lS,3R)-5,8-Dimethoxy-3-aceto-l-(2' ,6'-dideoxy-2'-iodo-L-lyxohexopyranoee)-isochroman (l'S,lS,3R)-3-aceto-l-(2',6'-dideoxy-2'-iodo-L-lyxohexopyranc
>
se)-5,8^ (1'S,1R,3S) and (l
,
S,lS,3R)-2,5-Dimethoxy-l-(2\6
,
-did_»xy-3\4'-dι__u^toxy-2'-bτomo-L- lyxohexopyranoβe)-3-acetoi8θchroman (1 'S, lS,3R)-2,5-Dimedιoxy-l-(2' ,6'-dideoxy-3' ,4
,
-diacetoxy-2'-bromo-L-lyxohexopyranoβe)-3- acetoisochroman (1 'S, lR,3S)-5,8-dioxo-l-(2\6'-dideoxy-3\4
,
-diatt
<
toxy-2
,
-broιno-L-l^^ dihydroisochroman
(l'S, lR,3S)-5,8-dioxo-3-aceto-l-(2
*
 ,6'-didepxy-3' ,4'-diacetoxy-2'-bromo-L-lyxohexopyranose 5,8- dihydroisochroman (l'S,lR,3S) and (l'S,lS,3R)-2,5-Dimedtoxy-3-aceto-l-(2',3',6'-trideoxy-2'-iodo-3'-trifiιιoroaceta.^
4'-0-βcetyl-L-lyxchexopyranose)-isochroman (l*S,lS,3R)-2,5-Dimedtoxy-3-aceto-l-(2*,3*,6'-trideoxy-2'-iodo-3'-trifluoιoa__«t_um lyxohexoρyranose)-isochroman (l'S,lR,3S)-5,8-Dimedrøxy-3-aceto-l-(2',3',6'-trideoxy-3'-tri^ lyxohexopyranose)-isochroman (l'S,lR,3S)-3-aceto-l-(2',3',6'-trideoxy 

287
SUBSTITUTE SHEET 


 5,8-dihydroiaochroman (l'S,lS,3R)-3-aceto-l-(2',3',6'-trideoxy-2'-iodo-3'-trifiuo_πoacetaιmά L-lyxote
5,8-dihydroisochroman (1'S,1S,3R) and (l'S,lR,3S)-5,8^Dimethoxy-3-«»to-l-(2',6'-dideoxy-3
,
,4'-diacetoxy-2'-io^ arabinohexopyranoβe) isochroman
(1 'S, lR,3S)-5,8-Dimethoxy-3-aceto-l-(2' ,6'-dideoxy-3',4'-diacetoxy-2'-iodo-L-s_π_binri»xopyr_moβe) isochroman (1'S,1R,3S) and (l'S,lS,3R 3-aceto-l-(2',6'-dideoxy-2'-iodo-L-arabinohexopyranose)-5,8-dioxo-5,8- dihydroisochroman (1'S,1S,3R) and (l'S,lR,3S)-5,8^1iιnethoxy-3-aceto-l-(2',6' bd_»xy-3',4'-di_κ»tox lyxohexopyranoβe) isochroman (1'S,1S,3R) and (l'S,lR,3S)-5,8-dimethoxy-3-aceto-l-(2',6'-dideoxy-L-lyxohexopyranose) isochroman (1'S,1S,3R) and (l'S,lR,3S)-5,8-dioxo-3-aceto-H2',6'-dideoxy-L-lyxriιexopyranose)-5,8- dihydroisochroman (1'S,1S,3R) and (l'S,lR,3S)-5,8-dioxo-3-«ceto-H2',6'-dideoxy-3',4'-dia^^ isochroman 3-aceto-5,8-dioxo-3,4,5,8-tetrahydro-lH-benzo-[2,3-c]-pyπn l-CH ^-BC :-4^iperidinemethanol]
-3-acetyl-5, 8-dimethoxy isochroman racemic (1R,3S,1'S) and (lS,3R,rS^Methyl-(l-[2 3\4\6'-t_ nki«)xy-3\4'-bi8-trifluoroa» mido-L- arabinohexopyτanoβe]-5,10-dioxo-3,4,5,10-tetrahydronaphthaleno-[2,3-c]
 pyran-3-yl) ketone l-0-[N-BC r-3-piperidinemethanol]-3-acetyl-5, 8-dimethoxy isochroman, mixture of isomers (1'S,1R,3S) and (1'S,1S,3R) - 2
t
5-Di_methoxy-l-
<
2
,
,6
,
-dideoxy-3
,
,4'- iιacetoxy-2'-iodo-L- lyxohexopyranoβe)-3-acetoisochroman
73. A compound according to claim 1 selected from the group consisting of :
Methyl (l-m__Λhoxy-5,10-dioxo-3,4,5,10-tetrahydro-lH-naphdιo[2,3-c]ρyran-3-yl) formate Mediyl (l-metiιoxy-5, 10-dioxo-5, 10-dihydro-lH-naphtho[2,3-c]
pyran-3-yl) formate l-Methoxy-5, 10-dioxo-5, 10-dihydro-lH-naphtho[2,3-c]pyτan-3-carboxybc acid (IS, 2'S, 3R) and (IR, 2'S, 3S)-methyl-(H -N-BOC-serine methyl ster]
-5,10-dioxo-3,4,5,10- tetrahydro-1-H-naphdιo [2,3-C] pyran-3-yl) ketone. 3,3 bis (medιoxycarbonyl)-5,10-dioxo-3,4,5,10-tetr___hydro-lH^ιaphtho-[2,3-c]
 pyran (1R.3S) and (lS,3R)-3-Aceto-5, 10-dioxo-l (4-chloroediylureido cyclohexyl-oxy)-3,4,5, 10-tetrahydro- lH-nahtho-[2,3-c]-pyran (3-N-imidazolylpropyl)-l-methoxy-5, 10-dioxo-5, 10-dihydro-lH-nιφhtho-[2,3-c]
-pyran-3-carboxamide (1 's, lS,3R)-l-(4'^MUtrobenzoyl-3'-trifluoroacetamido-2',3' ,5'-trideoxy-lyxohexopyranose)-3-πιethoxy- carbonyl-3-methyl-5, lO-dioxo-4,5, 10-trihydro-lH-naphtho-[2,3-c]-pyran
SUBSTITUTE SHEET 


 (rS,lR,3SH-(4'-p-*ύtrobenzoyl-3-trifiι_κ
>
ro^ toβyloxazolyl)-5, 10-dioxo-3,4,5, 10-tetrahydro-lH-naphdιo-[2,3-c]-pyran (l'S,lS,3R)-l-(4'-y^trobenzoyl-3-trifluorrιar^amido-2',3',6'-trideoxy-L-lyxohexopyranose)^^ toβyloxazolyl)-5, 10-dioxo-3 ,4,5, 10-tetrahydro-lH-napbtho-[2,3-c]
-pyran l-methoxy-3-acetyl-5, 10-dioxo-3,4,5, 10-tetrahydro-lH-n_φhtho-[2,3-c]-pyran
3-brornoa∞dιyl-l-ιnedκ)xy-5,10-dioxo-3,4,5,10-tet_rahydro-lH iaphdκ)-[2,3-c]-pyran Memyl-(6-hydroxy-5,10-dioxo-3,4,5,10-tetrahydronaphtho-[2,3-c]
-pyran-3-yl) ketone and methyl-(9- hydroxy-5,10-dioxo-3,4,5,10-tetrahydroιuqdidιo-[2,3-c]-pyran-3-yl) ketone (BCH-
2062) 3-ac*to-5,10-dioxo-3,4,5,10-tetrahydro-lH-naphtiκH2,3-c]-pyran
3-bromoacetyl-5, lO-dioxo-3,4,5, 10-tetr_dιydro-lH-___aphtho-[2,3-c]-pyran 3-(3 '-aminothiazolyl)-5, 10-dioxo-l ,3,4,5, 10-pentahydro-naphtho-[2,3-c]
-pyran
74. A compound according to claim 1 aelected from the group consisting of:
5,10-Dioxo-3-(propane-2-one)-l-(2',3',6'-trideoxy-3'-tri^ lyxohexo-pyranoβe)-3,4,5, 10-tetrahydro-lH-naphtho-[2,3-c] pyran (IR, 3SH-(2',3',6'-t__ideoxy-3'-trifluoιoaceta__rido-4'-C^p^ lyxohexopyranose-2-yl
>
-5, 10-dioxo-3,4,5, 10-tetrahydro-lH-naphtho [2,3-c] pyran
(IS, 3RH-(2\3 6'-trideoxy-3'-trifluoroacetanudo-4
,
-0-p-ri^ lyxoh»cφyπmose-2-yl)-5,10-dioxo-3,4,5,10-tetrahydro-lH4U_^tho-[2,3-c] pyran (l'S, IR, 3S)-5,10-dioxo-3-medιoxym_^yl-l-(2',3',6
,
-trideoxy-3'-trifluoroacetaιmά 4
,
-C^ ritrobenzoyl-L-lyxohexc pyranose)-3,4,5,10-tetπώydιx
>
-lH^ιaphtho-[2,3-c]-pyrω (l'S, IS, 3R)-5,10-dioxo-3-n_ethoxymeUιyl-l-(2',3',6'-trideoxy-3'-trifiuoroacetaιmά^^ ritrobenzoyl-I^lyxohex yranoβe)-3,4,5,10-tetrahydro-lH ia|riιUκ
>
-[2,3-c]-pyran (l'S, IR, 3R)-5,10-choxo-3-eώyl-l-(2',3\6'-trideoxy-3'-trifluoroa∞^ lyxohexopyranoβe)-3,4,5,10-tetrahydro-lH-naphtho-[2,3-c]
 pyran (l'S, IS, SS^S.lO-dioxo-S-ediyl-l^'.S β'-trideoxy-S'-trifluoroa∞tamido^'-O-p^trobenzoyl-L- lyxohexo-pyranose)-3,4,5, 10-tetrahydro-lH-naphto-[2,3-c]-pyran
(l'S, IS, 3R 5,l()-dioxo-3-i8opropyl-l-(2',3',6'-trideoxy-3'-trifiuoroaceta^ lyxohexo-pyrano_»)-3,4,5,10-tetrahydro-lH-naphtho-[2,3-c]-pyran (l'S, IR, 3S)-5,10-dioxo-3-isopropyl-l-(2',3',6'-trideoxy-3'-trifiuoroa∞^^ lyxohexopyranose)-3,4,5, 10-tetrahydro-lH-αaphtho-[2,3-c]
-pyran (l'S, IR, 3S 5,10-dioxo-3-i_topropenyl-l-(2',3',6
,
-trideoxy-3'-trifiuoιoacetaιmdo-4'-0-p-ri
L-lyxohexo-pyranose) 3,4,5, 10-tetrahydro-lH-naphtho-[2,3-c]-pyran (l'S, IS, 3R)-5,l(
>
-dioxo-3-isopropenyl-l-(2',3',6'-trideoxy-3'-trifluoroacetaιmdo-4'-0-p-ri
L-lyxohexo-pyranose) 3,4,5, 10-tetrahydro-lH-naphtho-[2,3-c]-pyran (l'S, IR, 3S)-iscφropyl-[l-(2\3\6
,
-trideoxy-3*-trifluoroaα!taιmdc
>
-4
,
-0-p-m
289
SUBSTITUTE SHEET 


 lyxohexopyr_uιoβe)-5,10-dωxo-3,4,5,10-tetrΛydr^ (l'S, IR, 3S), and (l'S, IS, 3R)-5,10-dioxo-3 soproρoxycaιbonyl-l-(2*,3',6'-trideoxy-
•
X trif.im 
m
-^.ar»iΛ ^Λ
,
 ^p^itrCmiMτ y l -lyτnhftτnpyr_ nBft)-3,4.5.10-te_trahvdro- lH-naphtho-{2,3-c]-pyτan (l'S, IS, 3R)-5,10-dioxo-3-iaopπφoxycarixmyl-l-(2',3 6'-trideoxy-3'^ ritrobenzoyl-I_Λyxohexopyranoβe)-3,4,5,10-tetrahyd_ro-lH^ (l'S, lS)-5,10-dioxo-3,3-dimethoxymethyl-l-(2',3'^ trobenzoyl-_ lyxohexcφyranose)-3,4,5,10-tetrahydro-lH-naphtho-[2,3-c]
 pyran (l'S, IR, 4R)-5,10-dioxo-4-eώyl-l-(2
,
,3',6'-trid_»xy-3
,
-triflι» lyχohexcφyranoβe)-3,4 ,10-te«nώydro-lH-r^Uκ
>
-[2,3-c]-pyran
(l'S, IR, 3S 5,l(
>
-dioxo-3-phenyloxym_ yl-l-(2
,
,3
,
,6'-t_ritø^ mtrobenzoyl-L-lyxohexopyranoβe 3,4,5,10-tetιahydro-lH-n_φhdκ
>
-[2,3-c] pyran (rS,lS,3S) and (l'-S,l-R,3-R
>
3-α2',3 6'-trid_»xy-3'-trifluoιoaα_taιri lyxohexopyranoβe)-5,10-dioxo-3,4,5,10-tetrahydronaphdκ
>
-[2,3-c]-pyran-3-yl)-propene (l'-S,l-R,3-R)-3-([2
,
,3\6'-trideoxy-3'-triflιιorc«cetamiά^
5,10-dioxo-3,4,5,10-tetπώydron_φhdιo-[2,3-c]
 yran-3-yl)-propene (l'-S, l-R,3-S)-methyl-(l-[2' ,3 ' ,6'-trideoxy-3 '-trifluo^^ dioxo-3,4,5,10-tetrahydronaphtho-[2,3-c]-pyran-3-yl
>
4cetcme (BCH-1620) (1'S,1S,3R) and (l'S,l-It_,3-R)-3-([2',3',6'-trideoxy-3'-trifiιιoroacetaιrido^'-hydroxy-L- lyhohexopyιanoβe]-5,10-dioxo-3,4,5,10-tetrahydronaphto-[2,3-c]
-pyran-3-yl)-propene
(1 'R, lR,3SX-3-aceto-5, 10-dioxo-l-(2-deoxy-2-crioroethylureid{
>
-4,6-benzybo^ne- -glucopyranoee)-
3,4,5,10-tetrahydro-lH-naphdκ
>
-[2,3-c]pyran (l'S,lR,3S)-l-4
,
-p-mtrobenzoyI-3'-trifluoroa∞taιmdo-2',3',6'-trideoxy-lyxohM carbonyl-3-methyl-5, lO-dioxo-4,5, 10-trihydro-lH-naphtho-[2,3-c]-pyran (l'S,lS,3SH-
<
4'-p-ritroben2Dyl-3'-trifluoroa-_-eta__riά^ carbonyl-3-methyl-5, 10-dioxo-4,5, 10-trihydro-lH-naphtho-[2,3-c]-pyran (l'S,lS,3S)-l-(4'-p-mtrobenzoyl-3'-trifluoroacetaιmdo-2',3',6'-trideoxy-U
5,10-dioxo-3,4,5,10-tetrahydro-lH-naphUκ 2,3-c]-thiopyran (1'S,1R,3R) and (l'S,lS,3SH-
<
4'-p- trobαιZDyl-3'-trifluoroa∞^ lyxohexopyτanoβe 3-acetyl-5,10-dioxo-3,4,5,10-tetrahydro-lH-naphdιo-[2,3-c]- thiopyran (1'S,1S,3S) and (l'S,lS,3R)-l-(4'-p^trobenzoyl-3'-trifluoroacetamido-2',3',6'-trideoxy- lyxohexopyranose)-3-acetyl-3-ιnethyl-5, 10-dioxo-4,5, 10-trihydro-lH-naphtho-[2,3-c]
- pyran (l'S,lS,3R)-l-(4'-p^trobenzoyl-3'-trifluo_roacetaιmdo-2',3',6'-trideoxy-lyxohexopy^ methyl-5, 10-dioxo-4,5, 10-trihydro-lH-n_φhdιo-[2,3-c]-pyran (1 'S,lR,3S)-l-(2' ,3 ' ,6'-trideoxy-4'-p-nitrobenzoyl-3 '-trifluoro-acetamido-L-lyxohexo pyranose)3- dimethyl-phoφhonoa(»tyl-5,10-dioxo-3,4,5,10-tetrahydro-lH^ιaphdιo-[2,3-c]
-pyran (1'S,1S,3R) and (l'S,lR,3S l-(2\3\6
,
-trideoxy-4
,
-p-mtiobenzoyl-3
,
-trifluoro-acetamido-L-lyxohexo
290
SUBSTITUTE SHEET 


 pyranoβe)3-dimethylphoqιhoooacetyl-5, 10-dioxo-3,4,5, 10-tetrahydro-lH-naphtho-[2,3- c]-pyran (l'S,lS,3R)-methyl-(6 and 9-hydroxy-l-
<
2\3\6'-trideoxy-3
,
-trifluoroac»taιrido-4'-C^-ritrobenzoyl-L- lyxc^xopyranc»e)-5,10-dioxo-3,4,5,10-tet_rahydι 
>
-lH^ι_φhdκ
>
-[2,3-c]-pyran-3-yl) ketone
75. A pharmaceutical composition according to claim 4 wherein said compound is combined witii an agent facibtating targetting of said combination to tumor or cancer ceUs.
76. A pharmaceutical composition according to claim 69, wherein said agent is selected from the groiφ consisting of monoclonal antibodies, polyclonal antibodies, proteins, and bpoβomes.
77. A pharmamntical composition according to claim 71, wherein said agent is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, proteins, and Uposomes.
78. A method of treatment of tumors or cancer said method comprising the step of administering to an animal, a therapeutically effective amount of at least one compound according to claim 1.
79. A method for the treatment of tumors or cancer aaid method comprising the step of administering to an animal, a tiierapeutically effective amount of at least one compound or combination of cbnicaby defective antitumor agents according to claim 2.
80. A method according to claim 79, wherein said animal is a mammal.
81. A method according to claim 80, wherein said mammal s a human.
291
SUBSTITUTE SHEET 

</CLAIMS>
</TEXT>
</DOC>
